



UNIVERSITI PUTRA MALAYSIA

***PROPHYLACTIC AND THERAPEUTIC EFFICACIES OF DIETARY
ZERUMBONE SUPPLEMENTATION ON THE PATHOGENESIS
OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS***

HEMN HASSAN OTHMAN HASSAN

FPV 2014 30



**PROPHYLACTIC AND THERAPEUTIC EFFICACIES OF DIETARY
ZERUMBONE SUPPLEMENTATION ON THE PATHOGENESIS
OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS**

By

HEMN HASSAN OTHMAN HASSAN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

November 2014

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright© Universiti Putra Malaysia



DEDICATION


This Dissertation is Dedicated to

My Beloved Wife

My Wonderful Triplets

My Lovely Parents and Siblings

All My Sincere Teachers, Lecturers and Friends



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

PROPHYLACTIC AND THERAPEUTIC EFFICACIES OF DIETARY ZERUMBONE SUPPLEMENTATION ON THE PATHOGENESIS OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS

By

HEMN HASSAN OTHMAN HASSAN

November 2014

Chairman: Professor Noordin Mohamed Mustapha, PhD

Faculty: Veterinary Medicine

Owing to the high incidence of cholesterol-induced cardiovascular disease particularly atherosclerosis. Furthermore, difficulty in finding a relatively efficacious, non toxic, readily available and cheap naturally existing antihyperlipidaemic and antiatherogenic complementary medicine warrant the search for such an agent. On the other hand, concerning the dangerous side effects of the chemical remedies utilized as a lipid lowering agents, therefore the current study was designed to investigate the prophylactic and therapeutic efficacies of dietary zerumbone (ZER) supplementation on the formation and development of atherosclerosis in rabbits fed with high cholesterol diet. A total of 72 New Zealand white rabbits (NZW) were divided randomly on two experimental studies carried out eight weeks apart.

First experiment was designed to investigate the prophylactic efficacy of ZER in preventing early developed atheromas lesion. A total of 30 healthy rabbits were equally allotted in to five groups comprising of six animals each, namely control (CN), hypercholesterolemic diet (HCD) and ZER preventive groups (ZPI, ZPII and ZPIII). The second experimental trial is aimed at investigating the therapeutic effect of ZER in reducing the atherosclerotic lesion progression and establishment, wherein 42 healthy NZW rabbits were equally assigned to seven groups comprising of six animals each, namely control (CN), high-cholesterol diet (HCD), ZER treatment groups (ZI, ZII and ZIII), Simvastatin (SIM) group (SG) and zerumbone-simvastatin (ZER-SIM) combination group (ZSG). Rabbits in CN group were fed a standard rabbit chow, whereas those in the HCD, ZPI, ZPII, ZPIII, ZI, ZII, ZIII, SG and ZSG given a cholesterol-rich diet (1%) (1g cholesterol/100g pellet). However, rabbits in the ZPI, ZPII and ZPIII preventive groups given ZER at a dose of 8, 16 and 20 mg/kg respectively, two weeks prior to the onset of lipidemia induction and then with the course of cholesterol-rich diet as a prophylactic measure. On the other hand, those in the ZI, ZII and ZIII treatment groups were given ZER at a dose of 8, 16 and 20 mg/kg

respectively, together with SIM at a dose of 15 and 5 mg/kg/day in SG and ZSG groups, respectively as a therapeutic measure.

Rabbits were sacrificed and thoracic aortas simultaneously with the vital internal organs were collected at 10 weeks post cholesterol-feeding for the prophylactic trial and 14 weeks concerning the therapeutic trial. In regard to the second trial, rabbits received treatments for about four weeks after cessation of cholesterol-rich diet at 10th weeks.

Following four weeks of supplementary treatment subsequent to high-cholesterol diet cessation at 10th week of 2nd experiment, ZER significantly reduce the serum lipid profile in all treated groups in a dose dependant manner as compared to non treated hypercholesterolemic animals. Sudanophilia, histopathological and ultrastructural changes show pronounced reduction in the plaque size in ZER medicated aortas. On the other hand, dietary supplementation of ZER for almost 10 weeks as a prophylactic measure indicates substantially decreasing in the lipid profile values and similarly plaque size in comparison with high-cholesterol non-supplemented rabbits.

Furthermore, the results of oxidative stress and antioxidant biomarkers evaluation indicate that ZER is a potent antioxidant in suppression the generation of free radicals in term of atherosclerosis prevention and treatment. ZER significantly reduces the value of MDA and augments the value of SOD. Zerumbone significantly reduces the incidence of inflammatory response in the process of atherosclerosis formation and development through significant suppression of proinflammatory mediators NF- κ B, iNOS and COX-2, in turn reduce the inflammatory cytokines secretion TNF- α , IL-6, IL-1, and IF- γ evaluated by Western blotting and enzyme immunoassay techniques respectively.

Conversely, reduction and suppression of inflammatory mediators will contribute to minimizing the chronic inflammatory cells mainly macrophages recruitment to the lesion and foam cell formation which is evident by immunohistochemistry and fluorescent assay of RAM-11. ZER significantly reduces the expression of RAM-11 in the intimal plaque in all ZER supplemented groups in a dose dependent manner.

Moreover, ZER significantly reduces the proliferation and migration of vascular smooth muscle fibers through immunohistochemical and fluorescent detection of HHF-35 toward the intimal layer via induction of apoptosis, which is evident by down regulation of Bcl-2 and up regulation of Bax significantly evaluated by Western blotting technique. Furthermore, *in vivo* antiproliferative assay of ZER determined morphologically by TUNEL assay.

In conclusion our data indicate that, dietary supplementation of ZER at doses of 8, 16 and 20 mg/kg alone as a prophylactic measure and as a supplementary treatment with simvastatin, significantly reduces early plaque formation, development, and

establishment via significant reduction in serum lipid profile together with suppression of oxidative damage, therefore alleviate atherosclerosis lesions. Simultaneously, ZER significantly suppresses inflammatory reaction within the plaque consequently prevent foam cell formation and plaque progression. Finally, ZER significantly lessens smooth muscle cells proliferation via induction of apoptosis eventually reduce the plaque size.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

KEBERKESANAN DIET ZERUMBON SEBAGAI PROFILAKSIS DAN TERAPEUTIK PERKEMBANGAN ATEROSKLEROSIS PADA ARNAB

Oleh

HEMN HASSAN OTHMAN HASSAN

November 2014

Pengerusi: Professor Noordin Mohamed Mustapha, PhD

Fakulti: Perubatan Veterinar

Berasaskan kepada insidens penyakit kardiovaskular teraruh-kolesterol terutamanya arteriosklerosis, satu kajian telah dibentuk untuk menyiasat kemujaraban profilaksis dan terapeutik pemberian zerumbon (ZER) rangsum terhadap pembentukan dan perkembangan arteriosklerosis pada arnab yang diberi rangsum tinggi kolesterol. Sebanyak 72 ekor arnab NZW dibahagikan secara rawak kepada dua kajian berjarak lapan minggu antaranya. Ujikaji pertama dibentuk untuk menyiasat kesan profilaksis kemujaraban ZER dalam mencegah pembentukan lesi awal arteroma. Sebanyak 30 ekor arnab sihat dibahagikan secara rata kepada lima kumpulan yang setiapnya mengandungi enam ekor iaitu, kawalan (CN), rangsum hiperkolesterol (HCD) dan kumpulan pencegahan ZER (ZPI, ZPII dan ZPIII).

Ujikaji kedua disasar untuk menyiasat kesan ZER dalam mengurangkan kemajuan serta pengukuhan lesi arteriosklerosis oleh ZER, dimana sebanyak 42 ekor arnab sihat NZW dibahagikan secara rata kepada tujuh kumpulan mengandungi enam ekor arnab setiap satu, iaitu kawalan (CN), rangsum kolesterol tinggi (HCD), rawatan ZER (ZI, ZII dan ZIII), SIM (SG) dan gabungan ZER-SIM (ZSG). Arnab dalam kumpulan CN diberi makan makanan piawai arnab manakala dalam kumpulan HCD, ZPI, ZPII, ZPIII, ZI, ZII, ZIII, SG dan ZSG masing-masing diberi rangsum tinggi kolesterol (1%) (1g kolesterol/100 g makanan). Bagaimanapun, arnab dalam kumpulan pencegahan ZPI, ZPII dan ZPIII masing-masing menerima ZER pada dos 8, 16 dan 20 mg/Kg, dua minggu sebelum kejadian aruhan lipidemia dan kemudiannya dengan rawatan rangsum tinggi kolesterol sebagai langkah pencegahan.

Sebaliknya, kumpulan rawatan ZI, ZII dan ZIII menerima ZER masing-masing pada dos 8, 16 dan 20 mg/Kg bersamaan dengan SIM pada dos 15 dan 5 mg/kg/day pada kumpulan SG dan ZSG sebagai langkah terapeutik. Selepas dikorbankan, aorta toraks

bersamaan dengan organ dalam penting lain diambil pada minggu ke 10 pasca pemberian kolesterol untuk kajian profilaksis. Dalam kajian terapeutik, arnab menerima rawatan selama empat minggu selepas 10 minggu pemberian rangsum kolesterol. Sepanjang empat minggu rawatan tambahan selepas pada pemberhentian rangsum tinggi kolesterol pada minggu ke-10 di ujikaji kedua, ZER telah mengurangkan profil lipid serum secara keertian pada semua kumpulan rawatan dalam pola bergantung dos berbanding dengan kumpulan kolesterol tinggi tak terawat. Sudanofilia, perubahan histopatologi and ultrastruktur menunjuk pengurangan ketara saiz plak pada aorta haiwan terawat ZER.

Sebaliknya, rawatan ZER selama hampir 10 minggu sebagai langkah profilaksis menandakan pengurangan ketara nilai profil lipid dan saiz palk berbanding dengan kumpulan tak terawat. Tambahan lagi, keputusan tegasan oksidatif dan biopenanda anti-pengoksidaan menunjukkan kemanjuran ZER dalam menindas penjanaan radikal bebas berasaskan pencegahan dan rawatan arteriosklerosis. ZER juga secara keertian telah mengurangkan nilai MDA dan dan mengganda nilai SOD. Zerumbon telah secara keertian mengurangkan insidens gerakbalas inflamasi dalam proses pembentukan dan perkembangan aterosklerosis melalui penindasan keertian perantara proinflamasi seperti NF- κ B, iNOS dan COX-2 yang seterusnya mengurangkan rembesan sitokin inflamasi seperti TNF- α , IL-6, IL-1, dan IF- γ yang dinilai melalui teknik asai penyerapan Western.

Pengurangan dan penindasan perantara inflamasi akan menyumbang kepada pengurangan sel inflamasi kronik terutamanya kemasukan makrofaj ke lesi dan pembedakan sel busa yang dibuktikan dengan imunohistokimia dan asai pendaflour RAM-11. ZER secara keertian telah mengurangkan penjelmaan RAM-11 pada plak intima di kesemua kumpulan pemberian tambahan ZER dengan pola bergantung dos. Tambahan lagi, ZER secara keertian mengurangkan pemprofiliteratan dan penghijrahan otot licin vaskular melalui pengesanan imunohistokimia dan pendaflour HHHF-35 terhadap lapisan intima melalui paruhan apoptosis yang terbukti dengan penurunanawalatur Bcl-2 dan tingkatkawalatur Bax secara keertian yang dinilai dengan teknik penyerapan Western. Tambahan lagi, anti-pemproliferatan *in vivo* oleh ZER yang dibuat secara morfologi dengan asai TUNEL.

Sebagai rumusan, data yang terhasil menunjukkan bahawa pemberian makan ZER sahaja pada dos 8, 16 and 20 mg/Kg untuk langkah profilaksis dan tambahan rawatan dengan SIM, mengurangkan pembedakan, perkembangan dan pengukuhan awal plak secara keertian melalui penurunan profil lipid berserta penindasan kerosakan oksidatif yang mengurangkan lesi arterioskeloris. Malah gabungan ZER menindas secara keertian tindakbalas inflamasi dalam plak yang akhirnya menghalang pembnetukan sel busa dan perkembangan plak. Akhir sekali, ZER secara keertian mengurangkan pemproliferatan otot licin melalui aruhan apoptosis yang mengecil saiz plak.

ACKNOWLEDGEMENTS

In the name of ALLAH most gracious and most merciful, as through his blessing, mercy, and boons I have been able to complete this thesis successfully as required in a most attractive and outstanding country, Malaysia (Pearl of the Orient). This thesis is the end of my long journey in obtaining my Degree of Philosophy in Pathology.

Initially, I would like to thank my advisor, Prof. Dr. Noordin Muhamed Mustapha, for his support, his guidance, his patience, and his mentorship. Prof has been a great mentor, teacher, and an awesome friend. I feel lucky to had the opportunity to have a guru who listened to my personal and professional challenges and gave me advice to help me learn and improve, not only as a scientist, but as an individual as well. I would like to submit my utmost appreciation to my supervisory committee members, Dr. Hazilawati Hamzah, Ph.D. and Prof. Dr. Md Zuki Abu Bakar for all of their precious advices, guidance, collaboration, and mentorship. I couldn't have asked for a better committee and I'm certainly would like to thank all of them deeply for the constant support in progressing me from zero to hero. My research would not be possible if not for the assistance of many other people. I wish to express my gratitude to all working staff in the Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia including Mr. Mohamed Halmi Bin Othman, Mr. Abdullah Bin Mison, and Mr. Arman Addelan in Hematology Laboratory; moreover, Mrs. Jamilah Jahari, Mrs. Latifah Mohd Hanan, and Mr. Mohd Jamil Samad from Laboratory of Histopathology for their continuous assistance and providing me with complete support in term of using laboratory facilities.

I would like to acknowledge Miss Kunnasunthary from Laboratory of Anatomy together with Mrs. Amlizawaty Amzah, Mrs. Maizatul Akmal, and Mr. Abdul Rashid from laboratory of Parasitology for providing invaluable assistance in utilizing the Image Analyzer and Fluorescent Microscopy. I wish to express my deep gratitude to all staffs of Microscopy Unit, Institute of Bioscience, Universiti Putra Malaysia, especially Mrs. Aminah Jusoh for her generous assistance in performing the Electron Microscopy technique. Exceptional thanks will due to Dr. Tan Sheau Wei from Laboratory of Vaccines & Immunotherapeutic for her invaluable assistance and guides in performing the Gene Expression part of my study.

During this work, I have collaborated with many colleagues for whom I have great regards specifically my best fellow Miss. Yasameen for her continous support and encouragement during the experimental period. Proudly, I would especially like to send my sincere acknowledgements oversea due to my best friend forever Othman Jalal Ali for his loyalty and honesty in taking care of my stuffs back there in my country unconditionally. I'm also glad to express my grateful thank to Mr. Daran Tawfiq Faraj, Mrs. Zuhra Omer Faraj, Mr. Meeran Daran Tawfiq, Mr. Sarwar Othman Faraj and Mrs. Sozan Mohammad Faraj, whom sincerely spate me with their care, support, entertain and gently love.

Last, but not least, I would like to express my deep thanks and appreciation to my Idol, raw model and number one motivator, my wife Heshu Suliman Rahman, since, this work would not have been possible without her continuous support and encouragement.



This thesis was submitted to the senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirements for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Noordin Mohamed Mustapha, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Chairman)

Md Zuki Abu Bakar, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

Hazilawati Hamzah, PhD

Senior Lecturer
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work
- quotations, illustrations and citations have been duly referenced
- the thesis has not been submitted previously or concurrently for any other degree at any institutions
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be owned from supervisor and deputy vice –chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: _____ Date: _____

Name and Matric No: : Hemn Hassan Othman, GS24515

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: _____

Name of
Chairman of
Supervisory
Committee: _____

Signature: _____

Name of
Member of
Supervisory
Committee: _____

Signature: _____

Name of
Member of
Supervisory
Committee: _____

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iv
ACKNOWLEDGMENTS	vi
APPROVAL	viii
DECLARATION	x
LIST OF TABLES	xvi
LIST OF FIGURES	xvii
LIST OF ABBREVIATIONS	xxxii
CHAPTER	
1 GENERAL INTRODUCTION	1
2 LITERATURE REVIEW	6
2.1 Atherosclerosis	6
2.1.1 Introduction	6
2.1.2 History and Theories of Atherosclerosis	6
2.1.3 Atherosclerosis Plaque Morphology	7
2.1.4 Plaque Rupture	7
2.1.5 Lesions and Mechanism of Atherosclerosis Development	7
2.1.6 Classification of Atherosclerotic Lesions	8
2.1.7 Risk Factors Associated With Atherosclerosis	9
2.1.7.1 Elevated serum Cholesterol and ox-LDL	10
2.1.8 Hypothesis of Atherosclerosis	10
2.2 Inflammation and Atherosclerosis	11
2.2.1 Inflammation in the Initiation of Atherosclerosis	11
2.3 Hypercholesterolemia and Atherosclerosis	13
2.4 Oxidative Stress and Atherosclerosis	14
2.5 Apoptosis in Atherosclerosis	15
2.6 Therapeutic Approach of Atherosclerosis	15
2.7 Natural Dietary Product	16
2.8 Zingiber Ginger	16
2.9 <i>Zingiber Zerumbet</i> (L.) Smith	17
2.10 Zerumbone	18
2.10.1 Chemical Characteristics of Zerumbone	20
2.10.2 General Medicinal Properties of Zerumbone	20
2.11 Simvastatin	21
3 GENERAL MATERIALS AND METHODS	22
3.1 Materials	22
3.1.1 Chemicals and Reagents	22
3.1.2 Apparatuses	22
3.2 Methods	23
3.2.1 Isolation and Characterization of Purified Zerumbone	23
3.2.1.1 Zerumbone Extraction	23

3.2.1.2	Preparation of Zerumbone Stock Solution for HPLC	23
3.2.1.3	HPLC Validation and Zerumbone Purity Determination	23
3.2.2	Preparation of Zerumbone Solution	24
3.2.2	Preparation of Simvastatin Solution	24
3.2.4	Zerumbone and Simvastatin Administration	24
3.2.5	Zerumbone Toxicity Assay	25
3.2.6	Preparation of 1% High-Cholesterol Diet	25
3.2.7	Animal and Management	26
3.2.8	Pilot Study	26
3.2.9	Experimental Design	27
3.2.9.1	Prophylactic Experiment	27
3.2.9.2	Therapeutic Experiment	28
3.2.10	Sampling	30
3.2.10.1	Body weight and Feed Intake	30
3.2.10.2	Clinical Signs	30
3.2.10.3	Blood Sampling	30
3.2.10.4	Preparation of Serum and Plasma	31
3.2.10.5	Preparation of Blood Hemolysates	31
3.2.10.6	Serum Lipid Profile Analysis	31
3.2.10.7	Termination of Experiment	31
3.2.10.8	Tissue Collection and Preservation	32
3.2.10.9	Preparation and Cleaning of Aorta	32
3.2.10.10	Preparation of Tissue Homogenate	33
3.2.10.11	Gross Pathology	33
3.2.10.12	Histopathology	34
3.2.10.13	Assessment of Atherosclerotic Plaque	34
3.2.10.14	Macroscopic Atheroma Plaque Quantification	34
3.2.10.15	Semiquantitative Evaluation of Microscopic Atherosclerotic Lesions	35
3.2.10.16	Transmission Electron Microscope (TEM)	35
3.2.10.17	Scanning Electron Microscope (SEM)	35
3.2.10.18	Immunohistochemistry Assay (IHC)	35
3.2.10.19	Immunofluorescence Assay (IFA)	36
3.2.10.20	In Situ TdT-mediated dUTP Nick End Labelling (TUNEL Assay)	37
3.2.10.21	Immuno-Quantitative Evaluation of RAM-11 and HHF-35	38
3.2.10.22	Quantitative Assay of Apoptotic and Immuno-Fluorescent Cells	38
3.2.10.23	Estimation of Plasma Malondialdehyde (MDA) Concentration	39
3.2.10.24	Estimation of Erythrocyte-Superoxide Dismutase (E-SOD) Activity	39
3.2.10.25	Western Blotting	40
3.2.10.26	Enzyme Linked Immuno-Sorbent Assay	41
3.2.11	Statistical Analysis	41

4	ANTI-HYPERCHOLESTEROLEMIC AND ANTIOXIDANT EFFICACIES OF ZERUMBONE ON THE FORMATION, DEVELOPMENT AND ESTABLISHMENT OF ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS	42
4.1	Introduction	42
4.2	Materials And Methods	43
4.3	Results	43
4.3.1	Zerumbone Extraction and Characterization	43
4.3.2	Clinical Observation	44
4.3.3	Gross Pathology	45
4.3.4	Zerumbone Toxicity Assay	50
4.3.5	Prophylactic Trial	53
4.3.5.1	Body Weight	53
4.3.5.2	Feed Intake	53
4.3.5.3	Organ Weight	54
4.3.5.4	Serum Lipid Profile	56
4.3.5.5	Assessment of Atherosclerotic Plaque Lesion Area (Sudanophilia)	58
4.3.5.6	Histopathological Evaluation	61
4.3.5.7	Scanning Electron Microscopy Evaluation	64
4.3.5.8	Transmission Electron Microscopy Evaluation (TEM)	65
4.3.5.9	Lipid Peroxidation and Antioxidant Status	68
4.3.6	Therapeutic Trial	69
4.3.6.1	Body Weight and Feed Intake	69
4.3.6.2	Organ Weight	71
4.3.6.3	Serum Lipid Profile	73
4.3.6.4	Assessment of Atherosclerotic Plaque Lesion Area (Sudanophilia)	76
4.3.6.5	Histopathological Evaluation	79
4.3.6.6	Scanning Electron Microscopy Evaluation	84
4.3.6.7	Transmission Electron Microscopy Evaluation (TEM)	87
4.3.6.8	Lipid Peroxidation and Antioxidant Status	90
4.4	Discussion	91
5	ANTI-INFLAMMATORY AND ANTI-PROLIFERATIVE EFFICACIES OF ZERUMBONE ON THE INITIATION, PROPAGATION AND ESTABLISHMENT OF ATHEROSCLEROSIS IN HYPERCHOLESTEROLAEMIC RABBITS	96
5.1	Introduction	96
5.2	Materials and Methods	97
5.3	Results	97
5.3.1	Prophylactic Trial	97
5.3.1.1	Immunohistochemistry Assay (IHC)	97
5.3.1.2	Immunofluorescent Assay (IFA)	101
5.3.1.3	TUNEL Assay	105
5.3.1.4	Western Blotting Assay (Quantification of Protein Expression)	108

5.3.1.5	Sero-Immunological Analysis of Proinflammatory Cytokines (ELISA)	111
5.3.2	Therapeutic Trial	112
5.3.2.1	Immunohistochemistry Assay (IHC)	112
5.3.2.2	Immunoflourescent Assay (IFA)	118
5.3.2.3	TUNEL Assay	125
5.3.2.4	Western Blotting Assay (Quantification of Protein Expression)	129
5.3.2.5	Sero-Immunological Analysis of Proinflammatory Cytokines (ELISA)	132
5.4	Discussion	134
6	GENERAL DISCUSSION, CONCLUSION AND FUTURE WORKS	140
	REFERENCES	147
	APPENDICES	173
	BIODATA OF STUDENT	180
	LIST OF PUBLICATIONS	181
	LIST OF CONFERENCE PROCEEDINGS	182



LIST OF TABLES

Table		Page
2.1	Chemical Characteristic of ZER.	20
3.1	The experimental design of the prophylactic trial.	27
3.2	The experimental design of the therapeutic trial.	27
4.1	Estimation of ZER toxicity on liver and kidney function tests.	50
4.2	Macroscopical assessments of intimal atherosclerotic area by Sudan IV stain (Sudanophilia) to detect the area of lesion distribution.	59
4.3	Histological evaluation of the intimal-medial thickness and aortic atherosclerotic plaque scoring.	62
4.4	Macroscopical assessments of intimal atherosclerotic area by Sudan IV stain (Sudanophilia).	76
4.5	Histological assessment of the intimal-medial plaque thickness and lesion scoring of aortic atherosclerosis.	80
5.1	Effect of ZER supplementation on proinflammatory cytokines.	111
5.2	Effect of ZER and simvastatin treatment on proinflammatory cytokines.	134



LIST OF FIGURES

Figure		Page
2.1	Photograph of <i>Zingiber zerumbet</i> tree demonstrating the Inflorescence (yellow arrow) and the leaves (white arrow).	18
2.2	The chemical structure of ZER, a Southeast Asian ginger sesquiterpene.	19
3.1	Photograph demonstrating the technique of handling rabbits during force-feeding protocol. A: Showing the animal been placed in the Aluminium restrainer. B: Rabbit been fixed and immobilized within the restrainer. C: Showing the animal been posed in standing position with the head outside the restrainer. D: Displaying the rabbit been forced-feed through the angle of mouth with no resistance.	25
3.2	Flow chart represents the experimental diet feeding time line of prophylactic experiment.	28
3.3	Flow chart represents the experimental diet feeding time line of therapeutic experiment.	
3.4	Flow chart representing general study layout and experimental design.	30
3.3	Photographs demonstrating the procedure of aorta defating, cleaning and bringing out from the carcass during rabbit necropsy. (Yellow arrow) representing the heart, (black arrow) is indicating the aortic arch, and the (dashed black arrow) referring to thoracic aorta. (AAr): Aortic Arch. (TA): Thoracic Aorta. (AA): Abdominal Aorta. (FAB): Femoral Artery Bifurcation	33
4.1	Photograph representing pure colorless crystals of extracted ZER.	43
4.2	HPLC chromatograph demonstrating the purity of extracted ZER crystals. The purity (P) of ZER is 99.31% is reached in 5.347 minutes retention time (RT).	44
4.3	Photographs demonstrating the clinical observation throughout the two experiments. A: Normal pink slightly congested mucus membrane of a rabbit from NC group. B: Yellowish discoloration of a rabbit mucus membrane from HCD group. C, D: Alopecia area (blue arrows) beneath the lower jaw.	45
4.4	Photograph illustrating the gross morphological changes of liver and kidney. At necropsy, severe fatty change is observed in liver of a rabbit from HCD group compare to CN group. Kidneys of HCD group appear much smoother, enlarged, and pale in appearance compare to the control.	46

4.5	Photograph illustrating the morphological changes of spleen and testis. In HCD group spleen and testis appear smaller, with smooth bright oily surface, and pale yellowish in color compared to control group.	47
4.6	Photograph demonstrating the gross morphological lesions of heart in hypercholesterolemic rabbits from HCD group. A: The presence of congestive area (Black arrow) within the myocardium together with moderate fatty liver (yellow arrow). B: The moderate hydropericardium with fibrinous yellowish exudates around the heart (Dashed black arrow), together with pulmonary hemorrhage (dashed yellow arrow). C and D: Refers to a myocardial infarction evidenced by a focal grayish pale coagulative necrosis in the apex of the heart (black arrow) due to coronary stenosis by atherosclerotic plaque.	48
4.7	Photograph illustrating the gross morphological lesions observed in different experimental groups at animal necropsy. A: Severe and massive fatty liver syndrome (Black arrow), together with paled colored splenomegaly (yellow arrow). B: Presence of massive and severe yellowish discoloration enlarged liver (hepatomegaly) (Black arrow) particularly in rabbits from HCD group. C: Moderate fatty liver (black arrow) together with normal splenic texture and color, except for slight enlargement (yellow arrow). D: Presence of mild hepatic fatty change (black arrow), with enlarged necrotic pale spleen evident by the presence of multifocal pinpoint white dots appear on the splenic capsule (yellow arrow).	49
4.8	Photomicrograph of liver from, A: Control group; B: ZER-I (8 mg/kg); C: ZER-II (16 mg/kg); D: ZER-III (20 mg/kg). Liver sections in B, C and D show no significant lesions compare to control group, represented by normally arranged hepatocytes (H) around the central vein (CV) together with normal sinusoidal capillaries (S) and slightly increased number of Kupffer cells (KC). Scale bars: 100 μ m.	51
4.9	Photomicrograph of kidney from, A: Control group; B: ZER-I (8 mg/kg); C: ZER-II (16 mg/kg); D: ZER-III (20 mg/kg). Renal sections in B, C and D show no prominent lesions compare to control group, evident by normal glomeruli (G), Bowman's capsule (BC) and renal tubules (RT). Present of non significant congestion within the glomerular capillaries (GC) and some renal cast (RC) within the tubules in D group. Scale bars: 100 μ m.	52
4.10	Bar graph represents the mean body weight (kg/rabbit) that is estimated at W0, W5 and W10. Significant changes were seen only between HCD and ZPIII groups at W5 and W10 of the experimental period.	53
4.11	Bar graph represent the percentage of daily feed intake (100 g/rabbit) measured at W0, W5 and W10. Significant changes $P < 0.05$ is seen only in HCD group at W5 and W10.	54
4.12-A	Bar graphs represent effect of ZER supplementation on liver	55

and visceral fat weights. The control group CN shows the lowest $P < 0.05$ weight compare to that of HCD group.

- 4.12-B Bar graphs represent effect of ZER supplementation on heart, kidneys and spleen weights. The control group CN shows the lowest $P < 0.05$ weight compare to HCD group. 55
- 4.13-A Bar graph represents hypolipidemic effect of ZER on TC. The concentration of TC in HCD group shows highest value at W5 and W10. The percentage of TC significantly reduced in ZPI, II and III at W10 compare to HCD group. 56
- 4.13-B Bar graph represents effect of ZER supplementation on TG. TG concentration shows significant differences between all groups, with significant $P < 0.05$ reduction in ZPIII group. 57
- 4.13-C Bar graph represents antihypercholesterolaemic effect of ZER on LDL-C. ZPI, ZPII and ZPIII groups show significant reduction in LDL-C concentration at W5 and W10 compare to that of HCD group. 57
- 4.13-D Bar graph represents effect of ZER on HDL-C. HDL-C concentration shows no significant differences between ZPII and III at W5 and W10. Highest value of HDL-C demonstrates in HCD group. 58
- 4.14 Photograph demonstrates aortic arch of CN and HCD groups. A: Aortic arches stained with Sudan IV dye, reveal red elevated, irregular fatty streaks (black arrow) representing atherosclerotic lesion area (sudanophilia). B: Aortic arches of CN and HCD groups before staining with Sudan IV, demonstrate white-chalky lipid deposition area (black arrow) of early fatty streaks lesion. 59
- 4.15 Photograph reveals the density of Sudanophilic area distribution in the aortic arch, thoracic aorta, and abdominal aorta of hypercholesterolemic rabbits. The Black arrows represent the thickness of fatty streak deposited on the intimal surface taken in both sides (A and B). 60
- 4.16 Photograph of aortic arches stained with Sudan IV dye (Sudanophilia) reveals the effect of ZER supplementation on atherosclerotic plaque formation and development. Black arrows indicate the red fatty streaks were disseminated randomly on the intimal surface. The areas of fatty streaks distribution were significantly reduced in ZPI, II and III. 60
- 4.17 Photograph of aortic arches stained with Sudan IV dye (Sudanophilia). Black arrows represent the bright-red fatty streaks were distributed haphazardly on the intimal surface of HCD group. However, no atherosclerosis lesions were seen on the intimal surface of CN group. 61
- 4.18 Photomicrograph of aorta of CN and HCD groups. Aorta in 62

- HCD group demonstrate thick fibro-muscular plaque (P) nearly occupied the lumen consist of many lipid-laden foam cells (black arrow), and proliferated vascular smooth muscle cells toward the intima (Yellow arrow). Aorta in CN group shows no intimal lesion (I). L: Lumen; I: Intima; M: Media; A: Adventitia. H&E. Scale bar: 500 μ m.
- 4.19 Photomicrograph of aortas from HCD, ZPI, ZPII and ZPIII groups. Aortas in ZPI, II and III show significant reduction in the plaque (P) thickness and foam cells (black arrows) compare to the thick fibromuscular plaque of HCD group. L: Lumen; M: Media; A: Adventitia. H&E. Scale bar: 500 μ m. 63
- 4.20 Three-dimensional scanning electronmicrograph of aortas from CN and HCD groups. Aorta in HCD illustrates many elevated fatty streak masses represent the atherosclerotic plaques (P) (yellow arrows), whereas, aorta in CN group show no damage on the smooth intimal surface (I). (M) Represent the tunica media with clear circular arrangement of smooth muscle fibers. Outer most layers are the adventitia (A). (L) Lumen. Scale bar: CN: 500 μ m; HCD: 200 μ m. 64
- 4.21 Three-dimensional scanning electronmicrograph of aortas from HCD, ZPI, ZPII and ZPIII groups. Aortas from ZER supplemented groups reveal notable minimizing in the plaque size (P) together with pronounced reduction in fatty streak distribution (yellow arrows) compare to that of HCD. L: Lumen; M: Media; A: Adventitia. Scale bars: 200 μ m. 65
- 4.22 Ultrastructural electronmicrograph of endothelial cell (EC) of CN and HCD groups. CN demonstrate normal orientation of the EC on intact internal and external elastic lamellae (red and dashed red arrows). Normal heterochromatic nucleus (yellow arrow) lined with intact cell membrane (black arrow). HCD show massive endothelial cells fragmentation with necrotic debris (electrodense ED and electrotranlucent ET particles) distributed randomly all over the intima (yellow arrow). Numerous foam cells (red arrow) with intracytoplasmic lipid globules together with many scattered lipid droplet observed inside a necrotic ECs or freely within the deformed and fragmented necrotic remnant (dashed red arrow). L: Lumen. Scale bars: CN: 5000 nm; HCD: 10000 nm. 66
- 4.23 Ultrastructural electronmicrograph of aortic tunica media myofibril. A: HCD group show variable size demarcated lipid droplets (red arrow) within the myofibril dense cytoplasm (dashed red arrow). B: represents ZER supplemented group demonstrate obvious reduction in the number of lipid droplet (red arrow) within the cytoplasm (dashed red arrow). Scale bars: 2000 nm. 66
- 4.24 Ultrastructural electronmicrograph of aortic endothelial cell from HCD, ZPI, ZPII and ZPIII groups. ZPI illustrate pronounced reduction in the intimal degenerative and necrotic cellular debris (yellow arrow), together with intimal elastic 67

lamellae restoration (red arrow). ZPII demonstrate partial cellular repair evidenced by partially intact endothelial cell (black arrow) with reaggregated nuclear chromatin (yellow arrow). The EC rest on restored intact basal lamella (dashed red arrow). Electron dense proteinaceous ground substances disseminated diffusely under the internal elastic lamellae (red arrow). ZPIII display partial to semi-complete cellular repair supported by heterochromatic fully developed nuclei (yellow arrow) with electron translucent cytoplasm (red arrow), surrounded by clear white elastic internal and external elastic lamellae (dashed yellow and red arrows). Tunica intimal myofibrils restored their normal morphology (black arrow) with few lipid droplets excluded outside the muscle cells (dashed black arrow). L: Lumen. Scale bars: HCD and ZPII: 10000 nm; ZPI: 2000 nm; ZPIII: 5000 nm.

- 4.25 Bar graph represents effect of ZER on lipid peroxidation biomarker MDA. The values of MDA show significant reduction in ZPI, II and III at W5 and W10, which is more significant ($P < 0.05$) in ZPII and III at W10. 68
- 4.26 Bar graph represents the effect of ZER on the antioxidant biomarker SOD. In ZPI, II and III SOD activity show significant increment at W5 and W10, however the increase value is more significant ($P < 0.05$) in ZPIII group at W10. 69
- 4.27 Bar graphs represent the means of rabbit body weight (kg/rabbit) (A) and daily feed intake (100 g/rabbit/day) (B) estimated at W0, W10 and W14. No significant differences in body weight seen at W10 and W14. Feed intake reduced significantly in ZI, ZII, ZIII and ZSG groups at W14. 70
- 4.28 Bar graphs represent effect of ZER on liver, visceral fat (A), heart, kidneys and spleen (B) weight. The mean organ weights show significant $P < 0.05$ reduction in ZIII and ZSG groups. 72
- 4.29 Bar graphs represent hypolipidemic effect of ZER on TC (A) and TG (B). SG and ZSG groups show much significant $P < 0.05$ reduction in TC and TG values compare to other treatment groups 74
- 4.29 Bar graphs represent hypolipidemic effect of ZER on LDL-C (C) and HDL-C (D). SG and ZSG groups display significant $P < 0.05$ reductions in LDL-C. Similarly, HDL-C shows reduction SG and ZSG groups, however the reduced values are not significant as LDL-C. 75
- 4.30 Photograph of thoracic aorta stained with Sudan IV dye (Sudanophilia) shows the distribution of dense irregular red fatty streaks (black arrows) on the intimal surface in HCD group compare to above CN group with no atherosclerosis lesion area. 77
- 4.31 Photograph of thoracic aorta stained with Sudan IV dye (Sudanophilia) demonstrates the effect of ZER treatment on 78

- atherosclerotic fatty streaks development and establishment. The randomly disseminated bright red fatty streaks (black arrows) on the intimal surface significantly reduced in ZI, II and III as a dose dependant manner. The yellow arrow indicates area of no fatty streaks lesion.
- 4.32 Photograph of thoracic aorta stained with Sudan IV dye (Sudanophilia) demonstrates the effect of ZER and SIM treatment on atherosclerotic fatty streaks development and establishment. In SG group the red-stained fatty streaks (yellow arrows) were significantly minimized and become more restricted in their distribution. However, in ZSG group the fine light red fatty streak lesions (black arrows) were significantly reduced. 89
- 4.33 Photomicrograph of aorta of CN and HCD groups. Aorta in HCD group demonstrates nearly occupied thick fibro-muscular plaque (P), consist of many lipid-laden foam cells at the base (yellow arrow), highly proliferated VSMCs and fibroblasts toward the intima (black arrow), pinkish ground substances (dashed black arrow), and many lymphocytes at the top of the plaque (dashed yellow arrow). Aorta in CN group shows no lesion. L: Lumen; I: Intima; M: Media; A: Adventitia. H&E. Scale bars: 500 μ m. 81
- 4.34 Photomicrograph of aortas from HCD, ZI, ZII and ZIII groups. Aortas in ZI, II and III show significant reduction in the plaque (P) thickness and foam cells (black arrows) compare to the thick fibromuscular plaque of HCD group. Yellow arrow in ZI group refers to the proliferative VSMCs. L: Lumen; M: Media; A: Adventitia. H&E. Scale bars: 500 μ m. 82
- 4.35 Photomicrograph of aorta from SG and ZSG groups. Aortas in both SG and ZSG groups display significant reduction in foam cells (black arrow) and increase in pinkish ground substances (dashed black arrow). Plaque reduction is much prominent in ZSG group. L: Lumen; P: Plaque; M: Media; A: Adventitia. H&E. Scale bars: 500 μ m. 83
- 4.36 Three-dimensional scanning electronmicrograph of aorta from CN and HCD groups. Aorta in CN group shows no damage on the smooth intimal surface (I), with regular and clear circular arrangement of VSMCs (M). Aorta from HCD group illustrates many elevated cheesy-like fatty streak masses signify the atherosclerotic plaques (P) that in some area partially detached (yellow arrow). L: Lumen; M: Media; A (dashed yellow arrow): Adventitia. Scale bars: CN: 500 μ m; HCD: 200 μ m. 84
- 4.37 Three-dimensional scanning electronmicrograph of aortas from HCD, ZI, ZII and ZIII groups. Aortas from ZER treatment groups illustrate evident reduction in plaque size (P) (yellow arrows) compare to HCD group. Cross section through atheromas plaque show many empty spaces that stand for empty lipid vacuoles and foam cells. L: Lumen; M: Media; A 85

- (dashed yellow arrow): Adventitia. Scale bars: 200 μ m.
- 4.38 Three-dimensional scanning electronmicrograph of aortas in HCD, SG and ZSG groups. Aortas from SG and ZSG groups show pronounced reduction in plaque size (P) (yellow arrow) compare to HCD group, represents by increased number of empty spaces within the plaque (dashed yellow arrow). L: Lumen; M: Media; A: Adventitia. Scale bars: SG: 200 μ m; ZSG: 500 μ m. 86
- 4.39 Ultrastructural electronmicrograph of aortic endothelial cell (EC) in CN and HCD groups. CN illustrates normal orientation of the EC on intact internal and external elastic lamellae (black and dashed black arrows). Normal heterochromatic nucleus with nuclear membrane (red arrow) EC lined with intacked cell membrane (dashed red arrow). Yellow arrows represent aortic connective tissue. HCD shows diffuse endothelial cells destruction together with the disruption of basal lamina (yellow arrow). Presence of abundant of electrodense (ED) and electrotranlucent (ET) particles of necrotic debris represent fragmented necrotic remnant distributed randomly in between the internal and external elastic lamella (red arrow). Dashed yellow and red arrows indicate partially damaged external and internal elastic basal lamellae, respectively. L: Lumen. Scale bars: 5000 nm. 87
- 4.40 Ultrastructural electronmicrograph of aortic endothelial cell (EC) in HCD, ZI, ZII and ZIII groups. ZI illustrates prominent reduction in the intimal degenerative fragments and necrotic cellular debris together with the lessening of intimal lipid deposition (yellow arrows). Partial restoration of external and internal elastic lamellae (dashed yellow and black arrows. ZII demonstrates obvious diminution of foam cells, lipid vacuoles and fragmented cellular debris in tunica media (dashed yellow arrow). Black arrow refers to the fully regenerative internal elastic lamellae with clear demarcation. Dashed black arrow represents fragmented debris of SMCs and elastic fibers. Yellow arrow indicates elastic fiber remnant. ZIII reveals complete disappearing of necrotic cellular debris with clear and fully grown internal elastic lamellae (dashed yellow arrow). Black arrows indicate fragmented elastic fibers in the tunica media. Presence of some lipid droplet in the media (dashed black arrow). Presence of SMCs with heterochromatin nucleus (yellow arrow). EDB: Electrodense bodies of fragmented SMCs scattered randomly in the tunica media. ED: Electrodense necrotic debris of fragmented SMCs in the tunica media. ND: Necrotic debris in the tunica media. SMC: Smooth muscle cell. L: Lumen. Scale bars: HCD and ZI: 5000 nm; ZII: 2000 nm; ZIII: 1000 nm. 88
- 4.41 Ultrastructural electronmicrograph of aortic endothelial cell (EC) in HCD, SG and ZSG groups. SG shows complete reduction in lipid deposition together with partial restoration of EC architecture (dashed yellow arrow). Areas of electrodense granular materials in the tunica intima represent non denudated 89

necrotic EC (yellow arrows). Black arrows indicate complete and partial repair of internal and external elastic lamellae, respectively. Dashed black arrow represents fragmented debris of SMCs. ZSG demonstrates distinctive EC architectural restoration evident by dense heterochromatic nucleus (black arrow) together with the complete reformation of external and internal elastic lamellae (red and dashed red arrows), respectively. Dashed yellow arrow represents the connective tissue between the two basal lamellae. Dashed black arrow indicates the electro-lucent extracellular matrix of tunica media. SMC: Smooth muscle cells with fully developed nucleus and without nucleus (yellow arrows). EDB: Electrodense bodies of fragmented SMC debris floated in the tunica media. RBC: Red blood cells. L: Lumen. Scale bars: SG:1000 nm; ZSG: 2000 nm.

- 4.42 Bar graph represents effect of ZER and SIM on lipid peroxidation biomarker MDA. The values of MDA show significant dropping in all treatment groups at W14 compare to HCD group, which is more significant ($P < 0.05$) in ZIII and ZSG groups. 90
- 4.43 Bar graph represents the effect of ZER and SIM on the antioxidant biomarker SOD. All treatment groups demonstrate significant increment of SOD activity at W14 compare to HCD group, however the increase value is more significant ($P < 0.05$) in ZSG group. 91
- 5.1 Bar graph represents the quantification assay of immuno-reactive positive (IPC) and immuno-reactive negative (INC) cells with macrophage biomarker RAM-11. All ZER supplemented groups show significant reduction in the RAM-11 in a dose dependant manner compare to HCD group. 97
- 5.2 Photomicrograph of thoracic aortas represent immunohistochemical staining with RAM-11 antibody from CN and HCD groups. CN shows no immunopositive reactive cells (IPC). HCD displays massive and diffuse IPCs within thick rising plaque (P) indicated by deep brownish-stained macrophages (black and yellow arrows). L: Lumen; M: Media; A: Adventitia. Scale bars: 500 μm . 98
- 5.3 Photomicrograph of thoracic aortas from HCD, ZPI, ZPII and ZPIII groups represent immunohistochemical staining with RAM-11 antibody. Aortas in ZPI, II and III groups demonstrate significant reduction in plaque size (P) and the intensity of brownish color RAM-11 immunopositive foam cells compare to the thick plaque in HCD (black arrows). Obviously, there is no reaction in the muscularis layer (M). L: Lumen; M: Media; A: Adventitia. Scale bars: 500 μm 99
- 5.4 Bar graph represents the quantification assay of immuno-reactive positive (IPC) and immuno-reactive negative (INC) cells with VSMCs biomarker HHF-35. All ZER supplemented groups show significant reduction in the IPCs HHF-35 100

- biomarker in a dose dependant manner compare to HCD group.
- 5.5 Photomicrograph of thoracic aortas from CN and HCD groups represent immunohistochemical staining with HHF-35 alpha actin antibody. The CN group demonstrates no immunopositive reactive cells. The HCD group shows diffuse VSMCs proliferation indicated by significant increase in the intensity of HHF-35 biomarker brownish color in the tunica media (M), with obviously no reaction in the intimal thick plaque (P). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 500 μ m. 100
- 5.6 Photomicrograph of thoracic aortas from HCD, ZPI, ZPII and ZPIII represent immunohistochemical staining with HHF-35 alpha actin antibody. Aortas from ZPI, II and III groups show significant lessening in the number of immunoreactive positive cells together with the obvious reduction in the density of brown coloration of the tunica media as well as plaque (P) size (black arrows). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 500 μ m. 101
- 5.7 Bar graph represents the immunoquantitative assay of immunopositive fluorescent cells (IPFC) and immunonegative non-fluorescent cells (INNFC) cells of macrophage-specific protein biomarker RAM-11. Supplemented groups ZPI, II and III show significant $P < 0.05$ reduction in the mean percentage of RAM-11 compare to HCD group. 102
- 5.8 Photomicrograph of thoracic aortas from CN and HCD groups symbolize immunoflourescent staining with RAM-11 antibody. Control group shows no immunopositive reaction. HCD group demonstrate pronounced immuno-flourescent positive reactive cells with increase intensity and percentage of greenish-fluorochrome foam cells in the intimal plaque (P). L: Lumen; M: Media; Ad: Adventitia. Scale bars: CN: 200 μ m; HCD: 100 μ m. 102
- 5.9 Photomicrograph of thoracic aortas from HCD, ZPI, ZPII and ZPIII represent immunoflourescent staining with RAM-11 antibody. Aortas in ZPI, II and III groups demonstrate significant reduction in the macrophage-derived foam cells within the tunica intima compare to HCD group, indicated by low intensity of greenish-fluorochrome immuno-positive RAM-11 cells in the intimal plaque (P) (white arrows). L: Lumen; P: Plaque; M: Media; Ad: Adventitia. Scale bars: 200 μ m. 103
- 5.10 Bar graph represents the immunoquantitative assay of immunopositive fluorescent cells (IPFC) and immunonegative non-fluorescent cells (INNFC) cells of VSMCs specific protein biomarker HHF-35. All ZER supplemented groups ZPI, II and III show statistically significant $P < 0.05$ reduction in the mean percentage of VSMCs IPFCs in a dose dependant manner compare to HCD group. 104

- 5.11 Photomicrograph of thoracic aortas from CN and HCD groups illustrates immunofluorescent staining with HHF-35 antibody. Control group shows no immunopositive reaction in the muscularis layer. Aorta in HCD group reveals distinct immuno-fluorescent positive reaction with increase intensity and sharpness of greenish-fluorochrome highly proliferative VSMCs within the tunica media (white arrow). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μ m. 104
- 5.12 Photomicrograph of thoracic aortas from HCD, ZPI, ZPII and ZPIII groups represent immunofluorescent staining with HHF-35 alpha actin antibody. Aortas in ZPI, II and III groups show significant reduction in the percentage of immunoreactive greenish positive VSMCs together with the obvious lessening of greenish-fluorochrome proliferative biomarker compare to HCD group (white arrows). L: Lumen; P: Plaque; M: Media; Ad: Adventitia. Scale bars: 200 μ m. 105
- 5.13 Bar graph represents the quantification assay of apoptotic cells (APC) and non-apoptotic cells (NAPC) shows significant $P < 0.05$ increase of apoptotic cells in ZER supplemented groups compare to HCD group, the mean percentages of APC are more significant in ZPIII and II, respectively. 106
- 5.14 Photomicrograph of thoracic aortas from CN and HCD groups represent in vivo antiproliferative effect of ZER (TUNEL assay). Apparently, there is no or mild apoptotic reaction in CN and HCD aortas, evident by red color nuclei of VSMCs as well as foam cells within the intimal plaque (P) (white arrows). L: Lumen; M: Muscularis layer; Ad: Adventitia. Scale bars: CN: 100 μ m; HCD: 200 μ m. 106
- 5.15 Photomicrograph of thoracic aortas from HCD, ZPI, ZPII and ZPIII groups represent in vivo antiproliferative effect of ZER (TUNEL assay). Aortas in ZPI, II and III groups show significant augmentation in the number of apoptotic cells in both intimal plaque (P) and muscularis (M) evidently with increase in greenish-yellow to orange-color glistening apoptotic nuclei (white arrows) disseminated throughout the aortic sections. L: Lumen; M: Muscularis layer; Ad: Adventitia. Scale bars: 100 μ m. 107
- 5.16 Western blot image analysis from aortic tissue by chemiluminescent gel doc for NF- κ B, Cox-2, and iNOS. All ZER supplemented groups show significant reduction in the protein band thickness, which indicates downregulation of protein expression, particularly in ZPIII which is highly significant. 108
- 5.17 Bar graph represents protein transcription analysis in aortic tissue by Western blotting assay using Image J software. Data reveal significant ($P < 0.05$) suppression of NF- κ B, Cox-2, and iNOS proteins in ZER preventive groups compare to that of HCD group, in which the effect is more significant in ZPIII. 109

5.18	Western blot image analysis from aortic tissue by chemiluminescent gel doc for Bax and Bcl-2. Zerumbone supplementation significantly upregulate proapoptotic Bax expression and down regulate antiapoptotic Bcl-2 protein expression in dose dependant manner, indicated by thick bands in Bax and very thin bands in Bcl-2.	110
5.19	Bar graph represent protein transcription analysis in aortic tissue by Western blotting assay using Image J software. Data show significant (P<0.05) downregulation of Bcl-2 and up-regulation of Bax proteins ZP groups, compare to HCD group. The effect is more significant in ZPIII and II, respectively.	110
5.20	Bar graph represent serum proinflammatory cytokines (TNF- α , IFN- γ , IL-1, and IL-6) analysis by ELISA assay. Data reveal significant (P<0.05) reduction in the serum inflammatory cytokines in all ZER supplemented groups in a dose dependant manner compare to HCD group. However, more statistically significant reduction can be seen in ZPIII group.	112
5.21	Bar graph represents the quantification assay of immuno-reactive positive (IPC) and immuno-reactive negative (INC) cells with macrophage-specific protein biomarker RAM-11. All treatment groups demonstrate statistically significant reduction in RAM-11 expression compare to HCD group.	113
5.22	Photomicrograph of thoracic aortas from CN and HCD groups represent immunohistochemical staining with RAM-11 antibody. Control group shows no immuno-reactive positive cells (IPC). Aorta in HCD group present diffuse IPCs within thick rising plaque (P) indicated by deep brownish-stained macrophages-derived foam cells. L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μ m.	113
5.23	Photomicrograph of thoracic aortas from HCD, ZI, ZII and ZIII groups represent immunohistochemical staining with RAM-11 antibody. Aortas in ZI, II and III groups reveal significant reduction in plaque size (P) (black arrows) and the intensity of brownish color of immunopositive foam cells within the tunica intima compare to that of HCD group. Obviously, there is no reaction in the muscularis layer (M). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μ m.	114
5.24	Photomicrograph of thoracic aorta from SG and ZSG groups represent immunohistochemical staining with RAM-11 antibody. Aortas in SG and ZSG groups reveal reduction in RAM-11 immunopositive reactive cells compare to HCD group, however ZSG group shows more significant reduction in macrophage expression within the intimal plaque (black arrows), indicated by profound lessening in the reactive brownish staining intensity. L: Lumen; M: Media; Ad: Adventitia; P: Plaque. Scale bar: 200 μ m.	115
5.25	Bar graph represents the quantification assay of immuno-	116

- reactive positive (IPC) and immuno-reactive negative (INC) cells with VSMCs-specific protein biomarker HHF-35 alpha actin. All treatment groups show significant ($P < 0.05$) reduction in HHF-35 expression compare to HCD group.
- 5.26 Photomicrograph of thoracic aortas from CN and HCD groups represent immunohistochemical staining with HHF-35 alpha actin antibody. Aorta in CN demonstrates no immuno-reactive cells in the tunica media. Aorta in HCD displays diffuse VSMCs proliferation evident by significant increase in the intensity of HHF-35 biomarker brownish color in the tunica muscularis, with obviously no reaction in the intimal thick plaque (P). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μm . 116
- 5.27 Photomicrograph of thoracic aortas from HCD, ZI, ZII and ZIII represent immunohistochemical staining with HHF-35 alpha actin antibody. All aortas in treatment groups show significant lessening in the number of immunoreactive positive cells (IPCs) together with the obvious reduction in brownish stain intensity of the tunica media as well as plaque size (black arrow) compare to HCD group. L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μm . 117
- 5.28 Photomicrograph of thoracic aorta from SG and ZSG groups represent immunohistochemical staining with HHF-35 antibody. Aorta in ZSG group shows significant lessening in the intensity of immunoreactive brownish positive VSMCs biomarker HHF-35 in the tunica media. In SG group less significant reduction in HHF-35 reactive cells is observed than in ZSG group. However, both groups display anti HHF-35 expression compare to HCD group. L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μm . 118
- 5.29 Bar graph represents the immunoquantitative assay of immunopositive fluorescent cells (IPFC) and immunonegative non-fluorescent cells (INNFC) cells of macrophage RAM-11 biomarker. All treatment groups show statistically significant $P < 0.05$ reduction in the percentage of RAM-11 IPFCs in a dose dependant manner compare to HCD group. 119
- 5.30 Photomicrograph of thoracic aortas from CN and HCD groups represent immunofluorescent staining with RAM-11 antibody. Aorta in CN group shows no immunopositive reaction with RAM-11. Aorta in HCD group reveals significant immunopositive reactive RAM-11 cells with increase intensity of greenish-fluorochrome area in the intimal plaque (P) (white arrow). L: Lumen; M: Muscularis layer (Media); Ad: Adventitia. Scale bars: CN: 200 μm ; HCD: 100 μm . 119
- 5.31 Photomicrograph of thoracic aortas from HCD, ZI, ZII and ZIII groups represent immunofluorescent staining with RAM-11 antibody. Aortas in ZI, II and III demonstrate significant lessening in the formation of foam cells-macrophage origin in 120


- the tunica intima compare to HCD group, indicated by prominent reduction in the intensity of immuno-fluorescent RAM-11 positive greenish area (white arrows). L: Lumen; P: Plaque; M: Muscularis layer. Scale bars: 200 μ m.
- 5.32 Photomicrograph of thoracic aorta from SG and ZSG groups represent immunofluorescent staining with RAM-11 antibody. Aorta in SG group demonstrates less significant reduction in RAM-11 immunopositive reactive area compare to ZSG group within the intimal plaque (P) (white arrows). However, ZSG group shows more significant lessening in the intensity and percentage of immuno-fluorescent positive area compare to HCD group. L: Lumen; M: Media. Scale bars: HCD and SG: 100 μ m; ZSG: 200 μ m. 121
- 5.33 Bar graph represent the immunoquantitative assay of immunopositive fluorescent cells (IPFC) and immunonegative non-fluorescent cells (INNFC) cells of VSMCs HHF-35 biomarker. All treatment groups demonstrate statistically significant reduction in the percentage of VSMCs IPFCs in a dose dependant manner compare to HCD group. 122
- 5.34 Photomicrograph of thoracic aortas from CN and HCD groups represent immunofluorescent staining with HHF-35 antibody. Aorta in CN group shows no immunopositive reaction in the media. However, Aorta in HCD group reveals very apparent immuno-fluorescent positive reaction with increase intensity, sharpness, and area of greenish-fluorochrome highly proliferative VSMCs within the tunica media (white arrow). L: Lumen; M: Media; Ad: Adventitia. Scale bars: 200 μ m. 122
- 5.35 Photomicrograph of thoracic aortas from HCD, ZI, ZII and ZIII groups represent immunofluorescent staining with HHF-35 alpha actin antibody. All treatment groups demonstrate significant reduction in the immunoreactive greenish positive VSMCs in a dose dependant manner compare to HCD group, indicated by obvious attenuation in the area of greenish-fluorochrome proliferative biomarker within the muscularis layer (white arrows). L: Lumen; P: Plaque; M: Media; Ad: Adventitia. Scale bars: 200 μ m. 123
- 5.36 Photomicrograph of thoracic aorta from SG and ZSG groups represent immunofluorescent staining with HHF-35 alpha actin antibody. Aorta in ZSG group shows much significant reduction in the number of immuno-fluorescent positive cells compare to HCD group, whereas, the intensity and greenish stain of immunopositive reactive area still can be seen clearly within the muscularis layer of SG group (white arrows). L: Lumen; P: Plaque; M: Media. Ad: Adventitia. Scale bars: 200 μ m. 124
- 5.37 Bar graph represents the quantification assay of apoptotic cells (APC) and non-apoptotic cells (NAPC) shows significant 126

- $P < 0.05$ increment in the percentage of apoptotic cells in ZII and ZIII groups, as well as more significant in ZSG group compare to HCD group, however SG group reveal non significant change in APCs value.
- 5.38 Photomicrograph of thoracic aortas from CN and HCD groups represent in vivo antiproliferative effect of ZER (TUNEL) assay. Apparently, there is no or very mild apoptotic reaction in CN and HCD aortas, evident by red color nuclei of VSMCs as well as foam cell derived-macrophages within the intimal plaque (P) in HCD group (white arrows). M: Muscularis layer; L: Lumen; Ad: Adventitia. Scale bars: 100 μ m. 126
- 5.39 Photomicrograph of thoracic aortas from HCD, ZI, ZII and ZIII represent in vivo antiproliferative effect of ZER (TUNEL) assay. All treatment groups show significant escalation in the number of apoptotic cells in both intimal plaque and muscularis layer, manifested with higher percentage of greenish-yellow to orange-color glistening apoptotic nuclei (white arrows) disseminated throughout the aortic sections, particularly within the intimal plaque (P). M: Muscularis layer; L: Lumen. Scale bars: 100 μ m. 127
- 5.40 Photomicrograph of thoracic aorta from SG and ZSG groups represents in vivo antiproliferative effect of ZER (TUNEL) assay. Aorta in ZSG group shows much significant increase in the number of greenish-yellow to orange-color glistening apoptotic nuclei in both intimal plaque and muscularis layer (white and dashed arrows) compare to HCD and SG groups which show much mild apoptotic reaction within the media. L: Lumen; P: Plaque; M: Media. Ad: Adventitia. Scale bars: 100 μ m. 128
- 5.41 Western blot image analysis from aortic tissue by chemiluminescent gel doc for NF- κ B, Cox-2, and iNOS. All ZER treatment groups as well as SG group show significant reduction in the protein concentration compare to that of HCD group, which indicate protein downregulation, particularly in ZSG group which is more significant compare to SG group. 129
- 5.42 Bar graph represent protein transcription analysis in aortic tissue by Western blotting assay using Image J software. Data show significant ($P < 0.05$) suppression of NF- κ B, Cox-2, and iNOS proteins in treatment groups compare to HCD group, in which the values are more significant in ZIII and ZSG groups. 130
- 5.43 Western blot image analysis from aortic tissue by chemiluminescent gel doc for Bax and Bcl-2 proteins. All ZER treatment groups reveal significant up-regulation of Bax and down regulation of Bcl-2 proteins expression compare to HCD group, yet the results are more significant in ZIII and ZSG groups. 131
- 5.44 Bar graph represent protein transcription analysis in aortic tissue by Western blotting assay using Image J software. Data reveal significant ($P < 0.05$) suppression of Bcl-2 and over- 132

expression of Bax protein in all ZER treatment groups compare to HCD group. However, the results are more significant in ZIII and ZSG groups.

5.45 Bar graph represent serum proinflammatory cytokines (TNF- α , IFN- γ , IL-1, and IL-6) analysis by ELISA assay. Data reveal significant ($P < 0.05$) reduction in the serum proinflammatory cytokines in all treatment groups in a dose dependant manner compare to that of HCD group, which is more significant in ZSG group.

133



LIST OF ABBREVIATIONS

°C	Degree Celsius
®	Trade Mark
µg	Microgram
µl	Microlitre
µm	Micro Meter
2X	Two Fold
Å	Angstrom
AA	Arachidonic acid
ACS	Acute Coronary Syndrome
ACUC	Animal Care and Use Committee
ADP	Adenosine Di Phosphate
AGE	Advanced Glycation End Products
Alb	Albumin
ALL	Acute Lymphocytic Leukemia
ALP	Alkaline Phosphatase
ALT	Alanine Aminotransferase
Ang-II	Angiotensin-II
ANOVA	One-Way Analysis of Variance
apoA1	Apolipoprotein A1
AST	Aspartate Aminotransferase
Bax	Bcl ₂ Associated X Protein
BDMA	Benzyl Dimethyl Amine
BHT	Butylated Hydroxytoulene
CAD	Coronary Artery Disease
CHD	Coronary Heart Diseases
Cm	Centimeter
cm ²	Square Centimetre
COX-2	Cyclooxygenase -2
CPD	Critical Point Drier
Creat	Creatinine
CRP	C-Reactive Protein
Cu Kα	Copper Anode
CVD	Cardiovascular Disease
CXCR3	Chemokine Receptor Type 3
Cyt-c	Cytochrome C
DAB	3, 3'-Diaminobenzidine
DCs	Dendritic Cells
dNTP	Deoxyribonucleotide
DPX	Mounting Media And Section Adhesive
EDTA	Ethyl Diamine Tetra Acetic Acid
EE	Ethanolic Extract
EEZZ	Ethanolic Extract of Zingiber Zerumbet Rhizome
ELISA	Enzyme Linked Immunosorbant Assay
EM	Electron Microscopy
FGF	Fibroblast Growth Factors
FITC	Fluorescein Isothiocyanate
g	Gram

GGT	Γ-Glutamyl Transferase
GSH	Glutathione
h	Hour (S)
H&E	Haematoxylin And Eosin
HCD	High-Cholesterol Diet
HDL	High-Density Lipoprotein
HMG-CoA	3-Hydroxy-3-Methyl Glutaryl Coenzyme A
HPLC	High Performance Liquid Chromatography
HRP	Horse Radish Peroxidase
ICAM-1	Intercellular Adhesion Molecule 1
IDL	Intermediate Density Lipoprotein
IFA	Immunofluorescent Assay
IFN- γ	Interferon- γ
IHC	Immunohistochemistry
IL-1	Interleukin-1
IL-6	Interleukin-6
iNOS	Inducible Nitric Oxide Synthase
I κ B α	Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Inhibitor, Alpha
κ	Kappa
kDa	Kilo Dalton
Kg	Kilogram
KH ₂ PO ₄	Potassium Dihydrogen Phosphate
L	Litre
LOX-1	Lectin-Type Oxidized LDL Receptor 1
MCP-1	Monocyte Chemotactic Protein 1
MDA	Malondialdehyde
MeOH	Methanol
mg	Milligram
MI	Myocardial Infarction
min	Minute
mL	Millilitre
MM	Mucus Membrane
Mm	Micromolar
mm	Millimetre
MMP	Matrix Metalloproteinases
n	Number
NaCN	Sodium Cyanide
NADPH	Nicotinamide Adenine Dinucleotide Phosphate
NaOH	Sodium Hydroxide
NF- κ B	Nuclear Factor Kappa-Light-Chain-Enhancer Of Activated B Cells
NH ₄ Cl	Ammonium Chloride
nmol	Nanomole
NMR	Nuclear Magnetic Resonance
NO	Nitric Oxide
OD	Optical Density
Ox-LDL	Oxidized Low Density Lipoprotein
$P < 0.05$	Probability Values of Less Than Alpha 0.05
PBS	Phosphate Buffer Saline

PDGF	Platelet-Derived Growth Factor
PGE2	Prostaglandin E2
pH	Measurement For Hydrogen Ion Concentration
PI	Propidium Iodide
PPAR- α	Peroxisome Proliferator-Activated Receptor-Alpha
RNAase	Ribonuclease Enzyme
ROS	Reactive Oxygen Species
rpm	Revolution Per Minute
SDS-PAGE	Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis.
Sec	Second (S)
SEM	Scanning Electron Microscope
SMC	Smooth Muscle Cells
SOD	Superoxide Dismutase
SPSS	Statistical Package For The Social Sciences
T-cell	T Lymphocyte
TEM	Transmission Electron Microscopy
TNF- α	Tissue Necrotizing Factor-Alpha
TUNEL	Tdt-Mediated Dntp Nick-End Labelling
UPM	University Putra Malaysia
v/v	Volume To Volume
VCAM-1	Vascular Cell Adhesion Molecule-1
VEGF	Vascular Endothelial Growth Factor
VLDL	Very Low-Density Lipoprotein
VSMC	Vascular Smooth Muscle Cells
w/v	Weight To Volume
WB	Western Blotting
WHHR	Watanabe Heritable Hyperlipidemic Rabbit
WHO	World Health Organization
ZER	Zerumbone
ZZ	Zingiber Zerumbet (L.) Smith
β -actin	Beta Actin
γ	Gamma

CHAPTER ONE

GENERAL INTRODUCTION

Atherosclerosis is a complex, chronic, proliferative and accumulative inflammatory disorder with the involvement of immune system (Ross, 1999; Galkina and Ley, 2009). It is a disease of large and medium sized arteries characterized by focal intimal thickening of the arterial wall associated with lipid deposition in the form of elevated lipid-filled plaques called atheromas (Ross *et al.*, 1984). Necrosis and fibrosis that follow the fibro-fatty plaque progression probably will result in partial or complete occlusion leading to ischemia and infarction (Ross, 1993b). It is of greatest importance of cardiovascular disease (CVD) in humans and is considered a public health issue accounting for an estimated 50% of overall deaths in western countries (O'Connor *et al.*, 2001; Stocker and Keane, 2004).

It is generally believed that atherosclerosis is a chronic inflammatory response that is advanced by lifestyle-related disorders, such as elevated serum cholesterol particularly low density lipoprotein (LDL-cholesterol), hypertension, diabetes mellitus and cigarette smoking (Altman, 2003; Sata and Fukuda, 2011). Recently hyperhomocysteinemia (Faraci and Lentz, 2004) and infectious microorganisms such as Cytomegalovirus, herpesviruses, *Helicobacter pylori* and *Chlamydia pneumoniae* (Chiu, 1999; Ameriso *et al.*, 2001) are believed to be contributors to the initiation and development of atherosclerosis.

Numerous pathophysiological investigations in humans and animals led to the formulation of the response-to-injury hypothesis of atherosclerosis (Ross and Glomset, 1973), which principally proposed that endothelial denudation was the initial step in the process of atherogenesis (Ross and Glomset, 1976). This postulation supports the early theory suggesting that cellular responses in atherosclerosis are secondary in response to mechanical and/or toxic injuries leading to endothelial dysfunction (Von Rokitansky and Swaine, 1855). This is in contrast, to the postulated an initial and critical role of cellular pathology in the formation and development of atherosclerosis (Virchow, 1860), once more supported by Ross (Ross, 1999) and antithetical to the humoral pathology theory of the Rokitansky's school (Mayerl *et al.*, 2006).

Currently, large number of recent work emphasize that the chronic inflammatory reaction together with involvement of innate and adaptive immune response in association with the traditional risk factors play a pivotal role in the initiation and progression of atherosclerosis (Hansson and Libby, 2006; Kaperonis *et al.*, 2006; Libby, 2012). Atherogenesis comprises three fundamental stages, including intimal thickening, plaque development, and plaque destabilization-rupture (Sakata, 2012). The initial and earliest lesion of atherosclerosis the so-called fatty streaks (Ross *et al.*, 1984) is common in infant and young children (Napoli *et al.*, 1997). It is merely and simply an inflammatory lesion consisting of T-lymphocytes (T-cells), dendritic cells (DCs), and monocyte-deriving macrophages, with involvement of innate and adaptive immune systems (Hansson and Libby, 2006; Galkina and Ley, 2009).

As fatty streaks developed, in result of endothelial injury that accumulates lipid, extracellular lipid particularly low density lipid (LDL) modified by oxidative pathway and engulfed by macrophages to form immobile foam cells (Stary *et al.*, 1994). Cytokines, growth factors, adhesion molecules and chemotactic proteins are released by chronic inflammatory cells and denudated endothelial cells result in monocytes recruitment, extracellular matrix production and smooth muscle cells (SMCs) proliferation-migration and transformation to foam cells in the intima (Lusis, 2000).

Foam cells originated from transformed SMCs that are subjected to death by apoptosis (Okura *et al.*, 2000). Progression of atherosclerosis from early to advance lesions will initiate with the generation of lipid-rich core in the deep layer of thickened intima derived from dead foam cells containing necrotic tissues and free cholesterol crystals which is called atheroma, that wrapped by thick fibrous cap (Ross, 1993a). Continuous atheroma build up result in arterial luminal narrowing particularly in the coronary artery, and it is considered a primary cause of stable angina pectoris (Sakata, 2012).

Persistent recruitment of inflammatory cells into the lesion particularly macrophages render the fibrous cap thin and make the plaque weak in architecture (Lendon *et al.*, 1991), therefore, more vulnerable to rupture in response to the physical forces of blood flowing causes ulceration, hemorrhage, and thrombus formation, which result in sudden death from myocardial infarction and stroke (Ross, 1999). Coronary artery disease (CAD) arising from atherosclerosis is a leading cause of mortality worldwide. Currently available therapeutics against atherosclerosis is basically limited to alleviating the traditional risk factors such as hyperlipidemia and hypertension or controlling the thrombotic complications (Weber and Noels, 2011).

Treatment with statin drugs in patients with CAD shows a significant reduction in risk factors that is correlates to LDL-cholesterol, thereby limiting plaque development and reduces possibly of plaque rupture throughout its pleiotropic anti-inflammatory and antihypercholesterolaemic effects, endothelial dysfunction improvement, and reducing thrombogenicity (Ray and Cannon, 2005). Furthermore, monitoring high blood pressure with antihypertensive beta-blockers contributes to lower mortality from myocardial infarction and stabilized atheroprogession (Sipahi *et al.*, 2007). More recently, medication with artificial peptide-based high density lipoprotein (HDL)-like apolipoprotein as an additive in statin-treated patients exert a profound anti-inflammatory and lipid lowering effects (Navab *et al.*, 2010).

On the other hand, concerning the dangerous side effects of these chemical remedies such as high doses of statins in patients with high serum cholesterol have been found to cause striated muscle damage (Antons *et al.*, 2006), and increase the risk of rhabdomyolysis associated with neuropathy (Fadini *et al.*, 2010). In addition to the complicated nature and pathogenesis of atherosclerosis, involving oxidative stress damage, endothelial dysfunction (Victor *et al.*, 2009), elevated level of LDL-cholesterol and chronic inflammatory reaction (Libby *et al.*, 2002; Kaperonis *et al.*, 2006).

As a result, seeking a multifaceted natural product-based complementary and alternative herbal medicine, which is readily available, effective, and addressed all major risk factors with no toxic effects, was the best choice in providing an ideal remedy in the prevention and treatment of atherosclerosis (Zeng *et al.*, 2012).

The usage, interest, and self-administration of herbal medicine are widespread and most popular alternative therapy among patients under CVDs pharmacotherapy (Izzo *et al.*, 2005). Using natural compounds as a supplementary healthy diet is not a substitute for regular medical care, however, it is considered as a complementary and alternative medicine (Brown *et al.*, 2007). Medical herbs and plant foods such as fruits, vegetables, and spices contain many biologically active phytochemical compounds that have various health promoting effects (Lampe, 1999).

Zingiber zerumbet (L.) Smith belonging to Zingiberaceae, is an edible ginger, originating from South-East Asia has been cultivated thousands of years as a spice-food additive and for medical purposes (Vimala *et al.*, 1999). Whereas, approximately 161 species from 18 genera of this family are found in Peninsular Malaysia (Ruslay *et al.*, 2007). The extracts of *Zingiber zerumbet* rhizomes, have been used as a traditional medicine to treat various types of inflammatory mediated human ailments as a potent inflammatory suppresser contribute to down regulate the proinflammatory mediators such as prostaglandin E2 (PGE2) (Chien *et al.*, 2008).

Recently, the rhizome's extract have been extensively studied in multiple investigations for its effectiveness in a broad range of biological activities include antinociceptive (Sulaiman *et al.*, 2009), anti-inflammatory (Zakaria *et al.*, 2010), antioxidant (Yob *et al.*, 2011), antimicrobial (Habsah *et al.*, 2000), antifungal (Jantan *et al.*, 2003), antitumor (Kirana *et al.*, 2003) and antiplatelet aggregation (Jantan *et al.*, 2008). More recently, ethanolic extract of *Zingiber zerumbet* showed antihypercholesterolaemic property in rats fed a high-fat diet (Chang *et al.*, 2012).

Of all bioactive compound(s) isolated and identified from various extracts of *Zingiber zerumbet* rhizomes, zerumbone has been studied extensively due to its broad-spectrum biomedical properties. Zerumbone (ZER) is a crystalline, monocyclic, sesquiterpene, phytochemical substance that was first isolated as a major compound in 1960 from the essential volatile oil of rhizomes of *Zingiber zerumbet* (L.) smith (Kitayama *et al.*, 2003). It predominantly can be isolated from both leaves and rhizomes of the plant at approximately 36.98% and 46.83%, respectively (Bhuiyan *et al.*, 2008).

Numerous biological and therapeutical activities of ZER includes anticancer and antioxidant (Murakami and Ohigashi, 2006), anti-inflammatory (Somchit *et al.*, 2012), antinociceptive (Zakaria *et al.*, 2010), antimicrobial (Kader *et al.*, 2011), hepatoprotective (Fakurazi *et al.*, 2009), antiproliferative and apoptosis inducing agent (Sakinah *et al.*, 2007b) and immunomodulatory activities (Keong *et al.*, 2010) in a dose dependant manner. In addition, ZER has been demonstrated to attenuate inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression via modulation of nuclear factor kappa-B cells (NF-κB) activation (Takada *et al.*, 2005; Murakami and Ohigashi, 2007), beside its potent anti-inflammatory (Sulaiman *et al.*, 2010) and antioxidant (Murakami *et al.*, 2003) efficacy.

Additionally, antiproliferative and apoptotic inducing effects of ZER been approved against variety of organ carcinogenesis via down and up regulation of Bcl-2 and Bax, respectively (Murakami *et al.*, 2002; Takada *et al.*, 2005; Sakinah *et al.*, 2007a). Moreover, ZER evidently approved to suppress some cytokines that play a major role in the process of atherogenesis such as interleukin-6 (IL-6) (Abdelwahab *et al.*, 2012) and tissue necrotizing factor-alpha (TNF- α) (Chen *et al.*, 2011).

Depend upon the mentioned phytotherapeutic effects of ZER against proliferative and inflammatory diseases via suppression of proinflammatory mediators and cytokines (Sulaiman *et al.*, 2010). In addition to its active antioxidant property in suppressing free radicals generation and its potent antiproliferative activity via upregulation of proapoptotic genes (Murakami *et al.*, 2002). Furthermore, to date, no study has addressed the effect of ZER on serum lipid profile in relation to atherosclerosis progression in rabbits. Therefore, the general objective of this study is to investigate the prophylactic and therapeutic efficacies of dietary ZER supplementation on the development of atherosclerosis in rabbits fed with high cholesterol diet.

Problem Statement

Difficulty in finding a relatively efficacious, non-toxic, readily available, cheap, and naturally existing antiatherogenic and antihyperlipidaemic agent warrants the search for such an agent.

Hypothesis

Null Hypothesis

Zerumbone supplementation shows no lipid lowering effect and not an antiatherogenic agent, thus will not prevent and reduce the early development of atherosclerotic lesions in hypercholesterolemic rabbits.

Alternative or Research Hypothesis

Zerumbone will prevent and reduce the development of atherosclerotic plaques induced by high cholesterol diet via suppression and down regulation of proinflammatory mediators and cytokines thus inflammatory reaction. As well as, inducing apoptosis and reducing smooth muscle cell proliferation-migration in turn plaque propagation. Finally yet importantly, suppressing free radicals production hence, minimizing oxidative stress damage, and lowering lipid profile subsequently alleviate plaque development.

Aim and objectives

The main aim of the study is to evaluate the prophylactic and therapeutic efficiencies of ZER supplementation on the formation, development, and establishment of early atherosclerosis in rabbits fed with high-cholesterol diet with the following objectives:

- 1) To evaluate the antihypercholesterolaemic effect of dietary ZER supplementation on the initiation and propagation of atherosclerosis in cholesterol-fed rabbits.
- 2) To estimate the antioxidant efficacy of dietary ZER supplementation on the formation and development of atherosclerosis in hypercholesterolemic rabbits.
- 3) To assess the anti-inflammatory effect of ZER supplementation on the initiation and development of atherosclerosis in rabbits fed high-cholesterol diet.
- 4) To estimate the antiproliferative and apoptosis inducing effect of ZER supplementation on the formation and progression of atherosclerosis in rabbits on high-cholesterol diet.

REFERENCES

- Abdelwahab, S. I., Abdul, A. B., Al-Zubairi, A. S., Elhassan, M. M. and Syam, M. (2009). In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa). *Journal of Biomedicine and Biotechnology*, 18, 19.
- Abdelwahab, S. I., Abdul, A. B., Devi, N., Ehassan Taha, M. M., Al-Zubairi, A. S., Mohan, S., *et al.* (2010). Regression of cervical intraepithelial neoplasia by zerumbone in female Balb/c mice prenatally exposed to diethylstilboestrol: Involvement of mitochondria-regulated apoptosis. *Experimental and Toxicologic Pathology*, 62(5), 461-469.
- Abdelwahab, S. I., Abdul, A. B., Mohan, S., Taha, M. M. E., Syam, S., Ibrahim, M. Y., *et al.* (2011). Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells. *Leukemia Research*, 35(2), 268-271.
- Abdelwahab, S. I., Abdul, A. B., Zain, Z. N. M. and Hadi, A. H. A. (2012). Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. *International Immunopharmacology*, 12(4), 594-602.
- Abdul, A. B., Al-Zubairi, A., Tailan, N., Wahab, S., Zain, Z., Ruslay, S., *et al.* (2008). Anticancer activity of natural compound (zerumbone) extracted from Zingiber zerumbet in human HeLa cervical cancer cells. *International Journal of Pharmacology*, 4(3).
- Ahmed, R. S., Suke, S. G., Seth, V., Chakraborti, A., Tripathi, A. K. and Banerjee, B. D. (2008). Protective effects of dietary ginger (*Zingiber officinales* Rosc.) on lindane induced oxidative stress in rats. *Phytotherapy Research*, 22(7), 902-906.
- Akopov, S., Sercombe, R. and Seylaz, J. (1996). Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. *Cerebrovascular and Brain Metabolism Reviews*, 8(1), 11.
- Al-Saffar, F., Ganabadi, S., Fakurazi, S. and Yaakub, H. (2011). Zerumbone improved immunoreactivity of neuropeptides in monosodium iodoacetate induced knee osteoarthritis in rat. *African Journal of Biotechnology*, 10(18), 3646-3653.
- Al-Saffar, F., Ganabadi, S., Fakurazi, S. and Yaakub, H. (2011). Response of Hepatic Metabolizing Enzymes and Oxidative Stress in Orally Administrated Zerumbone Against MIA-Induced Osteoarthritis in Rats. *Journal of Animal and Veterinary Advances*, 10(5), 566-573.
- Al-Saffar, F., Ganabadi, S., Fakurazi, S., Yaakub, H. and Lip, M. (2010). Chondroprotective Effect of Zerumbone on Monosodium Iodoacetate Induced Osteoarthritis in Rats. *Journal of Applied Sciences Research*, 10(4), 248-260.
- Altman, R. (2003). Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. *Thrombosis Journal*, 1(1), 4.

- Ameriso, S. F., Fridman, E. A., Leiguarda, R. C. and Sevlever, G. E. (2001). Detection of *Helicobacter pylori* in human carotid atherosclerotic plaques. *Stroke*, 32(2), 385-391.
- Antons, K. A., Williams, C. D., Baker, S. K. and Phillips, P. S. (2006). Clinical perspectives of statin-induced rhabdomyolysis. *The American Journal of Medicine*, 119(5), 400-409.
- Auge, N., Garcia, V., Maupas-Schwalm, F., Levade, T., Salvayre, R. and Negre-Salvayre, A. (2002). Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 22(12), 1990-1995.
- Badimon, J., Fuster, V., Chesebro, J. and Badimon, L. (1993). Coronary atherosclerosis. A multifactorial disease. *Circulation*, 87(3 Suppl), II3-16.
- Baeuerle, P. A. and Henkel, T. (1994). Function and activation of NF-kappaB in the immune system. *Annual Review of Immunology*, 12(1), 141-179.
- Basak, S., Sarma, G. C. and Rangan, L. (2010). Ethnomedical uses of Zingiberaceous plants of Northeast India. *Journal of ethnopharmacology*, 132(1), 286-296.
- Behrendt, D. and Ganz, P. (2008). Oxidative stress and vascular disease. *Endothelial Dysfunctions in Vascular Disease*, 148-164.
- Bellas, R. E., Lee, J. S. and Sonenshein, G. E. (1995). Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. *Journal of Clinical Investigation*, 96(5), 2521.
- Bennett, M. R. and Boyle, J. J. (1998). Apoptosis of vascular smooth muscle cells in atherosclerosis. *Atherosclerosis*, 138(1), 3-9.
- Bhandari, U. and Pillai, K. (2005). Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia in diabetic rats. *Journal of Ethnopharmacology*, 97(2), 227-230.
- Bhandari, U., Sharma, J. and Zafar, R. (1998). The protective action of ethanolic ginger (*Zingiber officinale*) extract in cholesterol fed rabbits. *Journal of Ethnopharmacology*, 61(2), 167-171.
- Bhuiyan, M. N. I., Chowdhury, J. U. and Begum, J. (2008). Chemical investigation of the leaf and rhizome essential oils of *Zingiber zerumbet* (L.) Smith from Bangladesh. *Bangladesh Journal of Pharmacology*, 4(1), 9-12.
- Blanco-Colio, L. M., Villa, A., Ortego, M., Hernández-Presa, M. A., Pascual, A., Plaza, J. J., et al. (2002). 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. *Atherosclerosis*, 161(1), 17-26.

- Blaschke, F., Bruemmer, D., Yin, F., Takata, Y., Wang, W., Fishbein, M. C., *et al.* (2004). C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. *Circulation*, 110(5), 579-587.
- Blumenthal, R. S. (2000). Statins: effective antiatherosclerotic therapy. *American heart journal*, 139(4), 577-583.
- Bobryshev, Y. V. and Lord, R. S. (2005). Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. *Journal of Histochemistry & Cytochemistry*, 53(6), 781-785.
- Bocan, T., Bak Mueller, S., Mazur, M. J., Uhlendorf, P. D., Quenby Brown, E. and Kieft, K. A. (1993). The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. *Atherosclerosis*, 102(1), 9-22.
- Bonetti, P. O., Lerman, L. O. and Lerman, A. (2003). Endothelial dysfunction a marker of atherosclerotic risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 23(2), 168-175.
- Boyle, J. (2005). Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. *Current Vascular Pharmacology*, 3(1), 63-68.
- Brand, K., Page, S., Walli, A. K., Neumeier, D. and Baeuerle, P. A. (1997). Role of nuclear factor-kappa B in atherogenesis. *Experimental Physiology*, 82(2), 297-304.
- Brown, J., Cooper, E., Frankton, L., Steeves-Wall, M., Gillis-Ring, J., Barter, W., *et al.* (2007). Complementary and alternative therapies: survey of knowledge and attitudes of health professionals at a tertiary pediatric/women's care facility. *Complementary Therapies in Clinical Practice*, 13(3), 194-200.
- Bubici, C., Papa, S., Dean, K. and Franzoso, G. (2006). Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. *Oncogene*, 25(51), 6731-6748.
- Butt, M. S. and Sultan, M. T. (2011). Ginger and its health claims: molecular aspects. *Critical Reviews in Food Science and Nutrition*, 51(5), 383-393.
- Cai, Y., Luo, Q., Sun, M. and Corke, H. (2004). Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. *Life Sciences*, 74(17), 2157-2184.
- Campbell, J. H., Efendy, J. L., Smith, N. J. and Campbell, G. R. (2001). Molecular basis by which garlic suppresses atherosclerosis. *The Journal of Nutrition*, 131(3), 1006S-1009S.

- Carew, T. E., Schwenke, D. C. and Steinberg, D. (1987). Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. *Proceedings of the National Academy of Sciences*, 84(21), 7725-7729.
- Casscells, W., Naghavi, M. and Willerson, J. T. (2003). Vulnerable atherosclerotic plaque a multifocal disease. *Circulation*, 107(16), 2072-2075.
- Castelli, W. P. (1996). Lipids, risk factors and ischaemic heart disease. *Atherosclerosis*, 124, S1-S9.
- Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R. and Dake, M. D. (2001). Vascular endothelial growth factor enhances atherosclerotic plaque progression. *Nature Medicine*, 7(4), 425-429.
- Chane-Ming, J., Vera, R. and Chalchat, J.-C. (2003). Chemical composition of the essential oil from rhizomes, leaves and flowers of *Zingiber zerumbet* Smith from Reunion Island. *Journal of Essential Oil Research*, 15(3), 202-205.
- Chang, C. J., Tzeng, T.-F., Liou, S.-S., Chang, Y.-S. and Liu, I.-M. (2012). Regulation of lipid disorders by ethanol extracts from *Zingiber zerumbet* in high-fat diet-induced rats. *Food Chemistry*, 132(1), 460-467.
- Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., *et al.* (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *European Heart Journal*, 32(11), 1345-1361.
- Charlton-Menys, V. and Durrington, P. (2008). Human cholesterol metabolism and therapeutic molecules. *Experimental Physiology*, 93(1), 27-42.
- Charoenwanthanang, P., Lawanprasert, S., Phivthong-ngam, L., Piyachaturawat, P., Sanvarinda, Y. and Porntadavity, S. (2011). Effects of *Curcuma comosa* on the expression of atherosclerosis-related cytokine genes in rabbits fed a high-cholesterol diet. *Journal of Ethnopharmacology*, 134(3), 608-613.
- Chen, B.-Y., Lin, D. P.-C., Wu, C.-Y., Teng, M.-C., Sun, C.-Y., Tsai, Y.-T., *et al.* (2011). Dietary zerumbone prevents mouse cornea from UVB-induced photokeratitis through inhibition of NF- κ B, iNOS, and TNF- α expression and reduction of MDA accumulation. *Molecular Vision*, 17, 854.
- Chien, T., Chen, L., Lee, C., Lee, F. and Wang, C. (2008). Anti-inflammatory constituents of *Zingiber zerumbet*. *Food Chemistry*, 110(3), 584-589.
- Chisolm, G. M. and Steinberg, D. (2000). The oxidative modification hypothesis of atherogenesis: an overview. *Free Radical Biology and Medicine*, 28(12), 1815-1826.
- Chiu, B. (1999). Multiple infections in carotid atherosclerotic plaques. *American Heart Journal*, 138(5), S534-S536.

- Cipollone, F., Fazio, M. L. and Mezzetti, A. (2007). Oxidative stress, inflammation and atherosclerotic plaque development. *International Congress Series*, 1303, 35-40.
- Clarke, M. C., Figg, N., Maguire, J. J., Davenport, A. P., Goddard, M., Littlewood, T. D., *et al.* (2006). Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. *Nature Medicine*, 12(9), 1075-1080.
- Collins, T. and Cybulsky, M. I. (2001). NF- κ B: pivotal mediator or innocent bystander in atherogenesis? *Journal of Clinical Investigation*, 107(3), 255-264.
- Corti, R., Osende, J., Hutter, R., Viles-Gonzalez, J. F., Zafar, U., Valdivieso, C., *et al.* (2007). Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. *Atherosclerosis*, 190(1), 106-113.
- Cullen, P., Rauterberg, J. and Lorkowski, S. (2005). The pathogenesis of atherosclerosis. *In Atherosclerosis: Diet and Drugs*, 170, 3-70.
- Cunningham, K. S. and Gotlieb, A. I. (2004). The role of shear stress in the pathogenesis of atherosclerosis. *Laboratory Investigation*, 85(1), 9-23.
- Cushing, S. D., Berliner, J. A., Valente, A. J., Territo, M. C., Navab, M., Parhami, F., *et al.* (1990). Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proceedings of the National Academy of Sciences*, 87(13), 5134-5138.
- Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., *et al.* (2001). A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. *Journal of Clinical Investigation*, 107(10), 1255-1262.
- Darshan, S. and Doreswamy, R. (2004). Patented antiinflammatory plant drug development from traditional medicine. *Phytotherapy Research*, 18(5), 343-357.
- Davies, M. J. (2000). The pathophysiology of acute coronary syndromes. *Heart*, 83(3), 361-366.
- Davignon, J. and Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis. *Circulation*, 109(23 suppl 1), 27-32.
- De Angelis, G. (2004). The influence of statin characteristics on their safety and tolerability. *International Journal of Clinical Practice*, 58(10), 945-955.
- De Caterina, R., Libby, P., Peng, H.-B., Thannickal, V. J., Rajavashisth, T., Gimbrone Jr, M., *et al.* (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. *Journal of Clinical Investigation*, 96(1), 60.
- Dev, S. (1960). Studies in sesquiterpenes—XVI: Zerumbone, a monocyclic sesquiterpene ketone. *Tetrahedron*, 8(3), 171-180.

- Dev, S., Anderson, J. E., Cormier, V., Damodaran, N. and Roberts, J. D. (1968). Nuclear magnetic resonance spectroscopy. The conformational mobility of humulene and zerumbone. *Journal of the American Chemical Society*, 90(5), 1246-1248.
- Di Napoli, M., Papa, F. and Bocola, V. (2001). Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. *Stroke*, 32(1), 133-138.
- Dias, D. A., Urban, S. and Roessner, U. (2012). A historical overview of natural products in drug discovery. *Metabolites*, 2(2), 303-336.
- Dichtl, W., Dulak, J., Frick, M., Alber, H. F., Schwarzacher, S. P., Ares, M. P., *et al.* (2003). HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 23(1), 58-63.
- Dichtl, W., Nilsson, L., Goncalves, I., Ares, M. P., Banfi, C., Calara, F., *et al.* (1999). Very low-density lipoprotein activates nuclear factor- κ B in endothelial cells. *Circulation Research*, 84(9), 1085-1094.
- Doran, A. C., Meller, N. and McNamara, C. A. (2008). Role of smooth muscle cells in the initiation and early progression of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 28(5), 812-819.
- Duñg, N. X., Chiñh, T. D., Rañg, D. D. and Leclercq, P. A. (1993). The constituents of the rhizome oil of *Zingiber zerumbet* (L.) Sm. from Vietnam. *Journal of Essential Oil Research*, 5(5), 553-555.
- Duve, R. (1980). Highlights of the chemistry and pharmacology of wild ginger (*Zingiber zerumbet* Smith). *Fiji Agricultural Journal*, 42(1), 41-43.
- Dwarakanath, R. S., Sahar, S., Reddy, M. A., Castanotto, D., Rossi, J. J. and Natarajan, R. (2004). Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor- κ B (NF- κ B). *Journal of Molecular and Cellular Cardiology*, 36(4), 585-595.
- Dzau, V. J., Braun-Dullaues, R. C. and Sedding, D. G. (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. *Nature Medicine*, 8(11), 1249-1256.
- Eguchi, A., Kaneko, Y., Murakami, A. and Ohigashi, H. (2007). Zerumbone Suppresses Phorbol Ester-Induced Expression of Multiple Scavenger Receptor Genes in THP-1 Human Monocytic Cells. *Bioscience, Biotechnology, and Biochemistry*, 71(4), 935-945.
- Eid, E. E., Abdul, A. B., Suliman, F. E. O., Sukari, M. A., Rasedee, A. and Fatah, S. S. (2011). Characterization of the inclusion complex of zerumbone with hydroxypropyl- β -cyclodextrin. *Carbohydrate Polymers*, 83(4), 1707-1714.

- El-Sharaky, A., Newairy, A., Kamel, M. and Eweda, S. (2009). Protective effect of ginger extract against bromobenzene-induced hepatotoxicity in male rats. *Food and Chemical Toxicology*, 47(7), 1584-1590.
- Eto, M., Kozai, T., Cosentino, F., Joch, H. and Lüscher, T. F. (2002). Statin prevents tissue factor expression in human endothelial cells role of Rho/Rho-kinase and Akt pathways. *Circulation*, 105(15), 1756-1759.
- Fadini, G. P., Manzato, E., Crepaldi, C., de Kreutzenberg, S., Tiengo, A. and Avogaro, A. (2010). Two cases of statin-induced rhabdomyolysis associated with mononeuropathy. *Clinical Drug Investigation*, 30(5), 347-350.
- Fakurazi, S., Hairuszah, I., Lip, J. M., Shanthi, G., Nanthini, U., Shamima, A., *et al.* (2009). Hepatoprotective action of zerumbone against paracetamol induced hepatotoxicity. *Journal of Medical Sciences (Pakistan)*, 9(3), 161-164.
- Falk, E., Shah, P. and Fuster, V. (1996). Pathogenesis of plaque disruption. *Atherosclerosis and Coronary Artery Disease*, 2, 492-510.
- Faraci, F. M. and Lentz, S. R. (2004). Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. *Stroke*, 35(2), 345-347.
- Fearon, I. M. and Faux, S. P. (2009). Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. *Journal of Molecular and Cellular Cardiology*, 47(3), 372-381.
- Freedman, J. E. (2003). High-fat diets and cardiovascular disease Are nutritional supplements useful? *Journal of the American College of Cardiology*, 41(10), 1750-1752.
- Fruebis, J., Silvestre, M., Shelton, D., Napoli, C. and Palinski, W. (1999). Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits. *Journal of Lipid Research*, 40(11), 1958-1966.
- Fuhrman, B., Rosenblat, M., Hayek, T., Coleman, R. and Aviram, M. (2000). Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. *The Journal of Nutrition*, 130(5), 1124-1131.
- Fulda, S. and Vucic, D. (2012). Targeting IAP proteins for therapeutic intervention in cancer. *Nature Reviews Drug Discovery*, 11(2), 109-124.
- Galis, Z. S., Sukhova, G. K., Lark, M. W. and Libby, P. (1994). Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *Journal of Clinical Investigation*, 94(6), 2493.
- Galkina, E. and Ley, K. (2009). Immune and inflammatory mechanisms of atherosclerosis. *Annual Review of Immunology*, 27, 165.

- Gerrity, R. (1981). The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. *The American Journal of Pathology*, 103(2), 181.
- Giang, P. M., Son, P. T., Jin, H. Z., Lee, J. H. and Lee, J. J. (2009). Comparative study on inhibitory activity of zerumbone and zerumbone 2, 3-epoxide on NF- κ B activation and NO production. *Scientia Pharmaceutica*, 77, 589-595.
- Gilmore, T. D. (2006). Introduction to NF- κ B: players, pathways, perspectives. *Oncogene*, 25(51), 6680-6684.
- Gómez-Garre, D., Muñoz-Pacheco, P., González-Rubio, M., Aragoncillo, P., Granados, R. and Fernández-Cruz, A. (2009). Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. *British Journal of Pharmacology*, 156(8), 1218-1227.
- Gómez-Gerique, J. A., Ros, E., Oliván, J., Mostaza, J. M., Vilardell, M., Pintó, X., *et al.* (2002). Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. *Atherosclerosis*, 162(2), 245-251.
- Gómez-Hernández, A., Martín-Ventura, J. L., Sánchez-Galán, E., Vidal, C., Ortego, M., Blanco-Colio, L. M., *et al.* (2006). Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor- κ B. *Atherosclerosis*, 187(1), 139-149.
- Gotto, A. M. and Grundy, S. M. (1999). Lowering LDL Cholesterol Questions From Recent Meta-Analyses and Subset Analyses of Clinical Trial Data Issues From the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. *Circulation*, 99(8), e1-e7.
- Griendling, K. K. and FitzGerald, G. A. (2003). Oxidative stress and cardiovascular injury part II: animal and human studies. *Circulation*, 108(17), 2034-2040.
- Grosvenor, P. W., Supriono, A. and Gray, D. O. (1995). Medicinal plants from Riau Province, Sumatra, Indonesia. Part 2: antibacterial and antifungal activity. *Journal of Ethnopharmacology*, 45(2), 97-111.
- Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., *et al.* (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Molecular Cell*, 2(2), 275-281.
- Guevara, N. V., Chen, K.-H. and Chan, L. (2001). Apoptosis in atherosclerosis: pathological and pharmacological implications. *Pharmacological Research*, 44(2), 59-71.
- Guijarro, C., Blanco-Colio, L. M., Massy, Z. A., O'Donnell, M. P., Kasiske, B. L., Keane, W. F., *et al.* (1999). Lipophilic statins induce apoptosis of human vascular smooth muscle cells. *Kidney International*, 56, S88-S91.

- Habsah, M., Amran, M., Mackeen, M., Lajis, N., Kikuzaki, H., Nakatani, N., *et al.* (2000). Screening of Zingiberaceae extracts for antimicrobial and antioxidant activities. *Journal of Ethnopharmacology*, 72(3), 403-410.
- Hakimoğlu, F., Kızıl, G., Kanay, Z., Kızıl, M. and Isı, H. (2007). The effect of ethanol extract of *Hypericum lysimachioides* on lipid profile in hypercholesterolemic rabbits and its in vitro antioxidant activity. *Atherosclerosis*, 192(1), 113-122.
- Hamad, A., Qureshi, H. J., Hasan, S. and Sami, W. (2010). Assessment of oxidized low density lipoprotein, as atherosclerosis risk marker in type 1 diabetic children with short history of diabetes mellitus. *Pakistan Journal of Physiology*, 6(1).
- Hanada, T. and Yoshimura, A. (2002). Regulation of cytokine signaling and inflammation. *Cytokine & Growth Factor Reviews*, 13(4), 413-421.
- Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. *New England Journal of Medicine*, 352(16), 1685-1695.
- Hansson, G. K. and Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. *Nature Reviews Immunology*, 6(7), 508-519.
- Harvey, A. L. (2008). Natural products in drug discovery. *Drug Discovery Today*, 13(19), 894-901.
- Hayashi, T., Matsui-Hirai, H., Fukatsu, A., Sumi, D., Kano-Hayashi, H., Rani P, J. A., *et al.* (2006). Selective iNOS inhibitor, ONO1714 successfully retards the development of high-cholesterol diet induced atherosclerosis by novel mechanism. *Atherosclerosis*, 187(2), 316-324.
- Heistad, D. D., Wakisaka, Y., Miller, J., Chu, Y. and Pena-Silva, R. (2009). Novel aspects of oxidative stress in cardiovascular diseases. *Circulation journal: official journal of the Japanese Circulation Society*, 73(2), 201.
- Hemmerich, K., Suschek, C. V., Lerzynski, G. and Kolb-Bachofen, V. (2003). iNOS activity is essential for endothelial stress gene expression protecting against oxidative damage. *Journal of Applied Physiology*, 95(5), 1937-1946.
- Herman, R. J. (1999). Drug interactions and the statins. *Canadian Medical Association Journal*, 161(10), 1281-1286.
- Hernández-Presa, M. A., Martín-Ventura, J. L., Ortego, M., Gómez-Hernández, A., Tuñón, J., Hernández-Vargas, P., *et al.* (2002). Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. *Atherosclerosis*, 160(1), 49-58.
- Hernández-Presa, M. A., Ortego, M., Tuñón, J., Martín-Ventura, J. L., Mas, S., Blanco-Colio, L. M., *et al.* (2003). Simvastatin reduces NF- κ B activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. *Cardiovascular Research*, 57(1), 168-177.

- Hoffman, A., Spetner, L. and Burke, M. (2002). Redox-regulated mechanism may account for zerumbone's ability to suppress cancer-cell proliferation. *Carcinogenesis*, 23(11), 1961-1962.
- Holvoet, P., Mertens, A., Verhamme, P., Bogaerts, K., Beyens, G., Verhaeghe, R., *et al.* (2001). Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 21(5), 844-848.
- Huang, G.-C., Chien, T.-Y., Chen, L.-G. and Wang, C.-C. (2005). Antitumor effects of zerumbone from *Zingiber zerumbet* in P-388D1 cells *in vitro* and *in vivo*. *Planta Medica*, 71(03), 219-224.
- Ibrahim, H., Khalid, N. and Hussin, K. (2007). Cultivated gingers of peninsular Malaysia: utilization profiles and micropropagation. *The Gardens' Bulletin Singapore*, 59(1-2), 71-88.
- Ibrahim, M. Y., Abdul, A. B., Wahab, S. I. A., Elhassan, M. M., Alzubairi, A. S. and Syam, M. (2009). Attenuation of cisplatin induced hepatotoxicity in rats using zerumbone. *Research Journal Biological Sciences*, 4(7), 777-784.
- Itabe, H., Mori, M., Fujimoto, Y., Higashi, Y. and Takano, T. (2003). Minimally modified LDL is an oxidized LDL enriched with oxidized phosphatidylcholines. *Journal of Biochemistry*, 134(3), 459-465.
- Izzo, A. A., Di Carlo, G., Borrelli, F. and Ernst, E. (2005). Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. *International Journal of Cardiology*, 98(1), 1-14.
- Jang, D. S. and Seo, E.-K. (2005). Potentially bioactive two new natural sesquiterpenoids from the rhizomes of *Zingiber zerumbet*. *Archives of Pharmacal Research*, 28(3), 294-296.
- Jantan, I., Raweh, S. M., Sirat, H. M., Jamil, S., Mohd Yasin, Y., Jalil, J., *et al.* (2008). Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. *Phytomedicine*, 15(4), 306-309.
- Jantan, I., Yassin, M. S. M., Chin, C. B., Chen, L. L. and Sim, N. L. (2003). Antifungal activity of the essential oils of nine Zingiberaceae species. *Pharmaceutical Biology*, 41(5), 392-397.
- Jawien, A., Bowen-Pope, D. F., Lindner, V., Schwartz, S. M. and Clowes, A. W. (1992). Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. *Journal of Clinical Investigation*, 89(2), 507.
- Jessup, W. (1996). Oxidized lipoproteins and nitric oxide. *Current Opinion in Lipidology*, 7(5), 274-280.
- Kader, G., Nikkon, F., Rashid, M. A. and Yeasmin, T. (2011). Antimicrobial activities of the rhizome extract of *Zingiber zerumbet*. *Asian Pacific Journal of Tropical Biomedicine*, 1(5), 409-412.

- Kaliora, A., Dedoussis, G. and Schmidt, H. (2006). Dietary antioxidants in preventing atherogenesis. *Atherosclerosis*, 187(1), 1-17.
- Kaperonis, E., Liapis, C., Kakisis, J., Dimitroulis, D. and Papavassiliou, V. (2006). Inflammation and atherosclerosis. *European Journal of Vascular and Endovascular Surgery*, 31(4), 386-393.
- Kastelein, J. J., Akdim, F., Stroes, E. S., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F., *et al.* (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. *New England Journal of Medicine*, 358(14), 1431-1443.
- Keaney, J. F. (2005). Oxidative stress and the vascular wall NADPH oxidases take center stage. *Circulation*, 112(17), 2585-2588.
- Kenagy, R., Hart, C., Stetler-Stevenson, W. and Clowes, A. (1997). Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. *Circulation*, 96(10), 3555-3560.
- Keong, Y. S., Alitheen, N. B., Mustafa, S., Aziz, S. A., Rahman, M. A. and Ali, A. M. (2010). Immunomodulatory effects of zerumbone isolated from roots of Zingiber zerumbet. *Pakistan Journal of Pharmaceutical Sciences*, 23(1), 75-82.
- Kibbe, M., Billiar, T. and Tzeng, E. (1999). Inducible nitric oxide synthase and vascular injury. *Cardiovascular Research*, 43(3), 650-657.
- Kim, M., Miyamoto, S., Yasui, Y., Oyama, T., Murakami, A. and Tanaka, T. (2009). Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. *International Journal of Cancer*, 124(2), 264-271.
- Kim, S., Thuy, T. T. T., Lee, J.-H., Ro, J. Y., Bae, Y.-A., Kong, Y., *et al.* (2009). Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. *Experimental & Molecular Medicine*, 41(4), 277-287.
- Kirana, C., McIntosh, G. H., Record, I. R. and Jones, G. P. (2003). Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. *Nutrition and Cancer*, 45(2), 218-225.
- Kita, T., Nagano, Y., Yokode, M., Ishii, K., Kume, N., Ooshima, A., *et al.* (1987). Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. *Proceedings of the National Academy of Sciences*, 84(16), 5928-5931.
- Kitayama, T. (2011). Attractive reactivity of a natural product, zerumbone. *Bioscience, Biotechnology, and Biochemistry*, 75(2), 199-207.
- Kitayama, T., Okamoto, T., Hill, R. K., Kawai, Y., Takahashi, S., Yonemori, S., *et al.* (1999). Chemistry of zerumbone. 1. Simplified isolation, conjugate addition reactions, and a unique ring contracting transannular reaction of its dibromide. *The Journal of Organic Chemistry*, 64(8), 2667-2672.

- Kitayama, T., Yamamoto, K., Utsumi, R., Takatani, M., Hill, R. K., Kawai, Y., *et al.* (2001). Chemistry of Zerumbone. 2. Regulation of Ring Bond Cleavage and Unique Antibacterial Activities of Zerumbone Derivatives. *Bioscience, Biotechnology, and Biochemistry*, 65(10), 2193-2199.
- Kitayama, T., Yokoi, T., Kawai, Y., Hill, R. K., Morita, M., Okamoto, T., *et al.* (2003). The chemistry of zerumbone. Part 5: Structural transformation of the dimethylamine derivatives. *Tetrahedron*, 59(26), 4857-4866.
- Kockx, M. M. and Herman, A. G. (2000). Apoptosis in atherosclerosis: beneficial or detrimental? *Cardiovascular Research*, 45(3), 736-746.
- Kockx, M. M. and Knaapen, M. W. (2000). The role of apoptosis in vascular disease. *The Journal of Pathology*, 190(3), 267-280.
- Kong, L., Luo, C., Li, X., Zhou, Y. and He, H. (2013). The anti-inflammatory effect of kaempferol on early atherosclerosis in high cholesterol fed rabbits. *Lipids in Health and Disease*, 12(1), 115.
- Kutuk, O. and Basaga, H. (2003). Inflammation meets oxidation: NF- κ B as a mediator of initial lesion development in atherosclerosis. *Trends in Molecular Medicine*, 9(12), 549-557.
- Lampe, J. W. (1999). Health effects of vegetables and fruit: assessing mechanisms of action in human experimental studies. *The American Journal of Clinical Nutrition*, 70(3), 475s-490s.
- Lapenna, D., Ciofani, G., Pierdomenico, S. D., Giamberardino, M. A. and Cuccurullo, F. (2001). Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. *Free Radical Biology and Medicine*, 31(3), 331-335.
- Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. and Willoughby, D. A. (2001). Possible new role for NF- κ B in the resolution of inflammation. *Nature Medicine*, 7(12), 1291-1297.
- Le, N. A. (2006). Hyperlipidemia and cardiovascular disease. *Current Opinion in Lipidology*, 17(6), 702-704.
- Lee, R. T. (2005). Oxidative stress and atherosclerosis. *Current Atherosclerosis Reports*, 7(3), 242-248.
- Lee, R. T. and Libby, P. (1997). The unstable atheroma. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 17(10), 1859-1867.
- Lendon, C. L., Davies, M., Born, G. and Richardson, P. (1991). Atherosclerotic plaque caps are locally weakened when macrophages density is increased. *Atherosclerosis*, 87(1), 87-90.

- Li, H., Cybulsky, M. I., Gimbrone, M. and Libby, P. (1993). An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 13(2), 197-204.
- Li, J. W.-H. and Vederas, J. C. (2009). Drug discovery and natural products: end of an era or an endless frontier? *Science*, 325(5937), 161-165.
- Liang, J., Liu, E., Yu, Y., Kitajima, S., Koike, T., Jin, Y., *et al.* (2006). Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. *Circulation*, 113(16), 1993-2001.
- Liao, J. K. and Laufs, U. (2005). Pleiotropic effects of statins. *Annual Review of Pharmacology and Toxicology*, 45, 89.
- Libby, P. (2001). Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation*, 104(3), 365-372.
- Libby, P. (2002a). Atherosclerosis: The new view. *Scientific American*, 286(5), 46.
- Libby, P. (2002b). Inflammation in atherosclerosis. *Nature*, 420, 868-874.
- Libby, P. (2012). Inflammation in atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 32(9), 2045-2051.
- Libby, P. and Simon, D. I. (2001). Inflammation and thrombosis the clot thickens. *Circulation*, 103(13), 1718-1720.
- Libby, P., Geng, Y. J., Aikawa, M., Schoenbeck, U., Mach, F., Clinton, S. K., *et al.* (1996). Macrophages and atherosclerotic plaque stability. *Current Opinion in Lipidology*, 7(5), 330-335.
- Libby, P., Okamoto, Y., Rocha, V. Z. and Folco, E. (2010). Inflammation in atherosclerosis. *Circulation Journal*, 74, 213-220.
- Libby, P., Ridker, P. M. and Hansson, G. K. (2011). Progress and challenges in translating the biology of atherosclerosis. *Nature*, 473(7347), 317-325.
- Libby, P., Ridker, P. M. and Maseri, A. (2002). Inflammation and atherosclerosis. *Circulation*, 105(9), 1135-1143.
- Linton, M. F. and Fazio, S. (2003). Macrophages, inflammation, and atherosclerosis. *International Journal of Obesity & Related Metabolic Disorders*, 27(3), 35-40.
- Lu, H., Shi, J.-X., Zhang, D.-M., Wang, H.-D., Hang, C.-H., Chen, H.-L., *et al.* (2009). Inhibition of hemolysate-induced iNOS and COX-2 expression by genistein through suppression of NF- κ B activation in primary astrocytes. *Journal of the Neurological Sciences*, 278(1), 91-95.

- Luan, Z., Chase, A. J. and Newby, A. C. (2003). Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 23(5), 769-775.
- Luna, L. G. (1968). *Manual of Histologic Staining Methods ; of the Armed Forces Institute of Pathology*. (Vol. 3rd edition): Blakiston Division, McGraw-Hill.
- Luoma, J. S., Strålin, P., Marklund, S. L., Hiltunen, T. P., Särkioja, T. and Ylä-Herttuala, S. (1998). Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 18(2), 157-167.
- Lusis, A. J. (2000). Atherosclerosis. *Nature*, 407, 233-241.
- Mach, F. and Steffens, S. (2008). The role of the endocannabinoid system in atherosclerosis. *Journal of Neuroendocrinology*, 20(s1), 53-57.
- Mach, F., Sauty, A., Iarossi, A. S., Sukhova, G. K., Neote, K., Libby, P., *et al.* (1999). Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. *Journal of Clinical Investigation*, 104(8), 1041-1050.
- Madamanchi, N. R., Vendrov, A. and Runge, M. S. (2005). Oxidative stress and vascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 25(1), 29-38.
- Magura, L., Blanchard, R., Hope, B., Beal, J. R., Schwartz, G. G. and Sahmoun, A. E. (2008). Hypercholesterolemia and prostate cancer: a hospital-based case-control study. *Cancer Causes & Control*, 19(10), 1259-1266.
- Malloy, M. J. and Kane, J. P. (2012). Hyperlipidemia and cardiovascular disease. *Current Opinion in Lipidology*, 23(6), 591-592.
- Marklund, S. and Marklund, G. (1974). Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *European Journal of Biochemistry*, 47(3), 469-474.
- Mashour, N. H., Lin, G. I. and Frishman, W. H. (1998). Herbal medicine for the treatment of cardiovascular disease: clinical considerations. *Archives of Internal Medicine*, 158(20), 2225.
- Mayerl, C., Lukasser, M., Sedivy, R., Niederegger, H., Seiler, R. and Wick, G. (2006). Atherosclerosis research from past to present—on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. *Virchows Archive*, 449(1), 96-103.
- McGavin, M. D., Carlton, W. W. and Zachary, J. F. (2001). *Thomson's Special Veterinary Pathology* (Vol. 3rd). Philadelphia. USA Mosby-Year Book, Inc.

- McNamara, D. J. (2000). Dietary cholesterol and atherosclerosis. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, 1529(1), 310-320.
- Meisinger, C., Baumert, J., Khuseyinova, N., Loewel, H. and Koenig, W. (2005). Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. *Circulation*, 112(5), 651-657.
- Methe, H. and Weis, M. (2007). Atherogenesis and inflammation—was Virchow right? *Nephrology Dialysis Transplantation*, 22(7), 1823-1827.
- Mishra, B. B. and Tiwari, V. K. (2011). Natural products in drug discovery: Clinical evaluations and investigations. *Opportunity, Challenge and Scope of Natural Products in Medicinal Chemistry*, 661, 1-62.
- Moghadasian, M. H. (2002). Experimental atherosclerosis: a historical overview. *Life Sciences*, 70(8), 855-865.
- Moore, K. J. and Tabas, I. (2011). Macrophages in the pathogenesis of atherosclerosis. *Cell*, 145(3), 341-355.
- Muhammad Nadzri, N., Abdul, A. B., Sukari, M. A., Abdelwahab, S. I., Eid, E. E., Mohan, S., *et al.* (2013). Inclusion Complex of Zerumbone with Hydroxypropyl- β -Cyclodextrin Induces Apoptosis in Liver Hepatocellular HepG2 Cells via Caspase 8/BID Cleavage Switch and Modulating Bcl2/Bax Ratio. *Evidence-Based Complementary and Alternative Medicine*, 2013.
- Munoz, C., Pascual-Salcedo, D., Castellanos, M. d. C., Alfranca, A., Aragonés, J., Vara, A., *et al.* (1996). Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity. *Blood*, 88(9), 3482-3490.
- Murakami, A. (2009). Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. *Food Factors for Health Promotion*, 61, 193-203.
- Murakami, A. and Ohigashi, H. (2006). Cancer-preventive anti-oxidants that attenuate free radical generation by inflammatory cells. *Biological Chemistry*, 387(4), 387-392.
- Murakami, A. and Ohigashi, H. (2007). Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals. *International Journal of Cancer*, 121(11), 2357-2363.
- Murakami, A., Hayashi, R., Takana, T., Kwon, K. H., Ohigashi, H. and Safitri, R. (2003a). Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. *Biochemical Pharmacology*, 66(7), 1253-1261.

- Murakami, A., Takahashi, D., Kinoshita, T., Koshimizu, K., Kim, H. W., Yoshihiro, A., *et al.* (2002). Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the α , β -unsaturated carbonyl group is a prerequisite. *Carcinogenesis*, 23(5), 795-802.
- Murakami, A., Takahashi, D., Koshimizu, K. and Ohigashi, H. (2003b). Synergistic suppression of superoxide and nitric oxide generation from inflammatory cells by combined food factors. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, 523, 151-161.
- Murakami, A., Tanaka, T., Lee, J. Y., Surh, Y. J., Kim, H. W., Kawabata, K., *et al.* (2004). Zerumbone, a sesquiterpene in subtropical ginger, suppresses skin tumor initiation and promotion stages in ICR mice. *International Journal of Cancer*, 110(4), 481-490.
- Murakami, A., Tanaka, T., Lee, J. Y., Surh, Y. J., Kim, H. W., Kawabata, K., *et al.* (2004). Zerumbone, a sesquiterpene in subtropical ginger, suppresses skin tumor initiation and promotion stages in ICR mice. *International Journal of Cancer*, 110(4), 481-490.
- Nakajima, K., Nakano, T. and Tanaka, A. (2006). The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. *Clinica Chimica Acta*, 367(1), 36-47.
- Nakamura, Y., Yoshida, C., Murakami, A., Ohigashi, H., Osawa, T. and Uchida, K. (2004). Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes. *Federation of European Biochemical Societies Letters*, 572(1), 245-250.
- Nammi, S., Kim, M. S., Gavande, N. S., Li, G. Q. and Roufogalis, B. D. (2010). Regulation of Low-Density Lipoprotein Receptor and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Expression by Zingiber officinale in the Liver of High-Fat Diet-Fed Rats. *Basic & Clinical Pharmacology & Toxicology*, 106(5), 389-395.
- Nammi, S., Sreemantula, S. and Roufogalis, B. D. (2009). Protective Effects of Ethanollic Extract of Zingiber officinale Rhizome on the Development of Metabolic Syndrome in High-Fat Diet-Fed Rats. *Basic & Clinical Pharmacology & Toxicology*, 104(5), 366-373.
- Napoli, C., D'armiento, F., Mancini, F., Postiglione, A., Witztum, J., Palumbo, G., *et al.* (1997). Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. *Journal of Clinical Investigation*, 100(11), 2680-2690.

- Napoli, C., Glass, C. K., Witztum, J. L., Deutsch, R., D'Armiento, F. P. and Palinski, W. (1999). Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. *Lancet*, 354(9186), 1234.
- Navab, M., Shechter, I., Anantharamaiah, G., Reddy, S. T., Van Lenten, B. J. and Fogelman, A. M. (2010). Structure and function of HDL mimetics. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 30(2), 164-168.
- Ness, G. C., Zhao, Z. and Lopez, D. (1996). Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. *Archives of Biochemistry and Biophysics*, 325(2), 242-248.
- Newby, A. C. (2006). Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. *Cardiovascular Research*, 69(3), 614-624.
- Newby, A. C. (2012). Macrophages and atherosclerosis. *Inflammation and Atherosclerosis*, 17, 331-352.
- Newman, D. J. (2008). Natural products as leads to potential drugs: an old process or the new hope for drug discovery? *Journal of Medicinal Chemistry*, 51(9), 2589-2599.
- Nidhi, S., Preeti, S., Jasuja, N. D. and Joshi, C. (2013). Hypocholesterolemic and Antioxidant Potentials of Some Plants and Herbs: A Review. *Research & Reviews: Journal Of Zoological Sciences*, 1(2), 26-42.
- Nurulhuda, M., Azlan, A., Ismail, A., Amom, Z. and Shakirin, F. H. (2012). Cholesterol-lowering and Atherosclerosis Inhibitory Effect of Sibul Olive in Cholesterol Fed-rabbit. *Asian Journal of Biochemistry*, 7(2), 80-89.
- O'Connor, S., Taylor, C., Campbell, L. A., Epstein, S. and Libby, P. (2001). Potential infectious etiologies of atherosclerosis: a multifactorial perspective. *Emerging Infectious Diseases*, 7(5), 780.
- Ohkawa, H., Ohishi, N. and Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Analytical Biochemistry*, 95(2), 351-358.
- Ohta, H., Wada, H., Niwa, T., Kirii, H., Iwamoto, N., Fujii, H., *et al.* (2005). Disruption of tumor necrosis factor- α gene diminishes the development of atherosclerosis in ApoE-deficient mice. *Atherosclerosis*, 180(1), 11-17.
- Okura, Y., Brink, M., Itabe, H., Scheidegger, K. J., Kalangos, A. and Delafontaine, P. (2000). Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. *Circulation*, 102(22), 2680-2686.

- Ozaki, M., Kawashima, S., Yamashita, T., Hirase, T., Namiki, M., Inoue, N., *et al.* (2002). Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. *Journal of Clinical Investigation*, 110(3), 331-340.
- Ozgoli, G., Goli, M. and Simbar, M. (2009). Effects of ginger capsules on pregnancy, nausea, and vomiting. *The Journal of Alternative and Complementary Medicine*, 15(3), 243-246.
- Platt, N., Haworth, R., Darley, L. and Gordon, S. (2002). The many roles of the class A macrophage scavenger receptor. *International Review of Cytology*, 212, 1-40.
- Plenz, G., Dorszewski, A., Breithardt, G. and Robenek, H. (1999). Expression of type VIII collagen after cholesterol diet and injury in the rabbit model of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 19(5), 1201-1209.
- Prakash, R. O., Rabinarayan, A. and Kumar, M. S. (2011). Zingiber zerumbet (L.) Sm., a reservoir plant for therapeutic uses: A Review. *International Journal of Research in Ayurveda and Pharmacy*, 2, 1-22.
- Prasad, K. (1999). Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Circulation*, 99(10), 1355-1362.
- Prasad, K. (2008). Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Atherosclerosis*, 197(1), 34-42.
- Qiao, J.-H., Tripathi, J., Mishra, N. K., Cai, Y., Tripathi, S., Wang, X.-P., *et al.* (1997). Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. *The American Journal of Pathology*, 150(5), 1687.
- Rahman, H. S., Rasedee, A., How, C. W., Abdul, A. B., Zeenathul, N. A., Othman, H. H., *et al.* (2013). Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. *International Journal of Nanomedicine*, 8, 2769-2781.
- Ray, K. K. and Cannon, C. P. (2005). The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. *Journal of the American College of Cardiology*, 46(8), 1425-1433.
- Ross, R. (1993a). Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. *The American Journal of Pathology*, 143(4), 987.
- Ross, R. (1993b). The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature*, 362, 801-809.

- Ross, R. (1999). Atherosclerosis—an inflammatory disease. *New England Journal of Medicine*, 340(2), 115-126.
- Ross, R. and Glomset, J. (1976). The pathogenesis of atherosclerosis. *The New England Journal of Medicine*, 295(7), 369.
- Ross, R. and Glomset, J. A. (1973). Atherosclerosis and the arterial smooth muscle cell. *Science*, 180(4093), 1332-1339.
- Ross, R., Wight, T., Strandness, E. and Thiele, B. (1984). Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. *The American Journal of Pathology*, 114(1), 79.
- Ruslay, S., Abas, F., Shaari, K., Zainal, Z., Sirat, H., Israf, D. A., *et al.* (2007). Characterization of the components present in the active fractions of health gingers (*Curcuma xanthorrhiza* and *Zingiber zerumbet*) by HPLC–DAD–ESIMS. *Food Chemistry*, 104(3), 1183-1191.
- Sabu, M. (2003). Revision of the genus *Zingiber* in South India. *Folia Malaysiana*, 4(1), 25-52.
- Sadhu, S. K., Khatun, A., Ohtsuki, T. and Ishibashi, M. (2007). First isolation of sesquiterpenes and flavonoids from *Zingiber spectabile* and identification of zerumbone as the major cell growth inhibitory component. *Natural Product Research*, 21(14), 1242-1247.
- Sahebkar, A. (2011). Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, 17(2), 271.
- Sakata, N. (2012). AGEs and Atherosclerosis. *Anti-Aging Medicine*, 9(3), 89-95.
- Sakinah, S., Handayani, S. T. and Hawariah, L. (2007a). Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. *Cancer Cell International*, 7(4), 1-11.
- Sakinah, S., Nallappan, M., Pihie, A. H. L. and Hawariah, L. (2007b). Zerumbone exerts antiproliferative activity via apoptosis on HepG2 cells. *Malaysian Journal of Biochemistry and Molecular Biology*, 15(1), 19-23.
- Sandison, A. (1962). Degenerative vascular disease in the Egyptian mummy. *Medical History*, 6(1), 77.
- Sata, M. and Fukuda, D. (2011). Chronic inflammation and atherosclerosis: A critical role for renin angiotensin system that is activated by life-style related diseases. *Inflammation and Regeneration*, 31(3), 245-255.
- Schönbeck, U., Mach, F., Sukhova, G. K., Murphy, C., Bonnefoy, J.-Y., Fabunmi, R. P., *et al.* (1997). Regulation of Matrix Metalloproteinase Expression in Human Vascular Smooth Muscle Cells by T Lymphocytes A Role for CD40 Signaling in Plaque Rupture? *Circulation Research*, 81(3), 448-454.

- Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S. and Libby, P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. *The American Journal of Pathology*, 155(4), 1281-1291.
- Schulze, P. C. and Lee, R. T. (2005). Oxidative stress and atherosclerosis. *Current Atherosclerosis Reports*, 7(3), 242-248.
- Schwenke, D. C. and Behr, S. R. (1998). Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations. *Circulation Research*, 83(4), 366-377.
- Sehrawat, A., Arlotti, J. A., Murakami, A. and Singh, S. V. (2012). Zerumbone causes Bax-and Bak-mediated apoptosis in human breast cancer cells and inhibits orthotopic xenograft growth in vivo. *Breast Cancer Research and Treatment*, 136(2), 429-441.
- Seimon, T. and Tabas, I. (2009). Mechanisms and consequences of macrophage apoptosis in atherosclerosis. *Journal of Lipid Research*, 50(Supplement), S382-S387.
- Shamoto, T., Matsuo, Y., Shibata, T., Tsuboi, K., Nagasaki, T., Takahashi, H., *et al.* (2014). Zerumbone Inhibits Angiogenesis by Blocking NF- κ B Activity in Pancreatic Cancer. *Pancreas*, 43(3), 396-404.
- Sharma, I., Gusain, D. and Dixit, V. P. (1996). Hypolipidemic and antiatherosclerotic effects of *Zingiber officinale* in cholesterol fed rabbits. *Phytotherapy Research*, 10, 517-518.
- Sharma, N., Sharma, P., Jasuja, N. D. and Joshi, S. C. (2013). Hypocholesterolemic and Antioxidant Potentials of Some Plants and Herbs: A Review. *Research and Reviews: Journal of Zoological Sciences* 1(2), 26-42.
- Shimizu, T., Nakai, K., Morimoto, Y., Ishihara, M., Oishi, H., Kikuchi, M., *et al.* (2009). Simple rabbit model of vulnerable atherosclerotic plaque. *Neurologia Medico-Chirurgica*, 49(8), 327-332.
- Shiomi, M., Ito, T., Tsukada, T., Yata, T. and Ueda, M. (1994). Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 14(6), 931-937.
- Shiomi, M., Yamada, S. and Ito, T. (2005). Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. *Atherosclerosis*, 178(2), 287-294.
- Shukla, S. K., Gupta, S., Ojha, S. K. and Sharma, S. B. (2010). Cardiovascular friendly natural products: a promising approach in the management of CVD. *Natural Product Research*, 24(9), 873-898.

- Singh, C., Nongalleima, K., Brojendrosingh, S., Ningombam, S., Lokendrajit, N. and Singh, L. (2012). Biological and chemical properties of Zingiber zerumbet Smith: a review. *Phytochemistry Reviews*, 11(1), 113-125.
- Singh, U. and Jialal, I. (2006). Oxidative stress and atherosclerosis. *Pathophysiology*, 13(3), 129-142.
- Sipahi, I., Tuzcu, E. M., Wolski, K. E., Nicholls, S. J., Schoenhagen, P., Hu, B., *et al.* (2007). β -Blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. *Annals of Internal Medicine*, 147(1), 10-18.
- Sobal, G. and Sinzinger, H. (2005). Effect of simvastatin on the oxidation of native and modified lipoproteins. *Biochemical Pharmacology*, 70(8), 1185-1191.
- Soltero-Perez, I. (2002). Toward a new definition of atherosclerosis including hypertension: a proposal. *Journal of Human Hypertension*, 16, 23-25.
- Somchit, M., Mak, J., Ahmad Bustamam, A., Zuraini, A., Arifah, A., K, Adam, Y., *et al.* (2012). Zerumbone isolated from Zingiber zerumbet inhibits inflammation and pain in rats. *Journal of Medicinal Plants Research*, 6(2), 177-180.
- Song, L., Leung, C. and Schindler, C. (2001). Lymphocytes are important in early atherosclerosis. *Journal of Clinical Investigation*, 108(2), 251-259.
- Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., *et al.* (2001). Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 21(1), 115-121.
- Spiteller, G. (2005). Is atherosclerosis a multifactorial disease or is it induced by a sequence of lipid peroxidation reactions? *Annals of the New York Academy of Sciences*, 1043(1), 355-366.
- Srinivasan, K. and Sambaiah, K. (1990). The effect of spices on cholesterol 7 alpha-hydroxylase activity and on serum and hepatic cholesterol levels in the rat. *International Journal for Vitamin and Nutrition Research*, 61(4), 364-369.
- Sтары, H. (1983). Evolution of atherosclerotic plaques in the coronary arteries of young adults. *Arteriosclerosis* 3, 417A-421A.
- Sтары, H. (1987). Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. *Atherosclerosis*, 64(2), 91-108.
- Sтары, H. (1990). The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. *European Heart Journal*, 11(suppl E), 3-19.

- Stary, H., Blankenhorn, D., Chandler, A. B., Glagov, S., Insull Jr, W., Richardson, M., *et al.* (1992). A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation*, 85(1), 391.
- Stary, H., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., *et al.* (1995). A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 15(9), 1512-1531.
- Stary, H., Chandler, A. B., Glagov, S., Guyton, J. R., Insull, W., Rosenfeld, M. E., *et al.* (1994). A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 14(5), 840-856.
- Steinberg, D. (1997). Low density lipoprotein oxidation and its pathobiological significance. *Journal of Biological Chemistry*, 272(34), 20963-20966.
- Steinberg, D. (2002). Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. *Nature Medicine*, 8(11), 1211-1217.
- Steinberg, D. (2006). Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 coronary primary prevention trial ends it—almost. *Journal of Lipid Research*, 47(1), 1-14.
- Steiner, L., Kröncke, K.-D., Fehsel, K. and Kolb-Bachofen, V. (1997). Endothelial cells as cytotoxic effector cells: cytokine-activated rat islet endothelial cells lyse syngeneic islet cells via nitric oxide. *Diabetologia*, 40(2), 150-155.
- Stocker, R. and Keaney, J. F. (2004). Role of oxidative modifications in atherosclerosis. *Physiological Reviews*, 84(4), 1381-1478.
- Stoneman, V. E. and Bennett, M. R. (2004). Role of apoptosis in atherosclerosis and its therapeutic implications. *Clinical Science*, 107(4), 343-354.
- Sulaiman, M. R., Mohamad, T. A. S. T., Mossadeq, W. M. S., Moin, S., Yusof, M., Mokhtar, A. F., *et al.* (2009). Antinociceptive activity of the essential oil of *Zingiber zerumbet*. *Planta Medica*, 76(02), 107-112.
- Sulaiman, M. R., Perimal, E., Akhtar, M., Mohamad, A., Khalid, M., Tasrip, N., *et al.* (2010). Anti-inflammatory effect of zerumbone on acute and chronic inflammation models in mice. *Fitoterapia*, 81(7), 855-858.
- Sun, Y., Sheng, Q., Cheng, Y., Xu, Y., Han, Y., Wang, J., *et al.* (2013). Zerumbone induces apoptosis in human renal cell carcinoma via Gli-1/Bcl-2 pathway. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*, 68(2), 141-145.

- Sung, B., Murakami, A., Oyajobi, B. O. and Aggarwal, B. B. (2009). Zerumbone abolishes RANKL-induced NF- κ B activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. *Cancer Research*, 69(4), 1477-1484.
- Tabas, I. (1997). Free cholesterol-induced cytotoxicity: a possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions. *Trends in Cardiovascular Medicine*, 7(7), 256-263.
- Tabas, I. (2005). Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis the importance of lesion stage and phagocytic efficiency. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 25(11), 2255-2264.
- Tabas, I. (2009). Macrophage death and defective inflammation resolution in atherosclerosis. *Nature Reviews Immunology*, 10(1), 36-46.
- Tabas, I., Seimon, T., Timmins, J., Li, G. and Lim, W. (2009). Macrophage apoptosis in advanced atherosclerosis. *Annals of the New York Academy of Sciences*, 1173(s1), E40-E45.
- Tak, P. P. and Firestein, G. S. (2001). NF- κ B: a key role in inflammatory diseases. *Journal of Clinical Investigation*, 107(1), 7-11.
- Takada, Y., Murakami, A. and Aggarwal, B. B. (2005). Zerumbone abolishes NF- κ B and I κ B α kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. *Oncogene*, 24(46), 6957-6969.
- Tanaka, T., Shimizu, M., Kohno, H., Yoshitani, S.-i., Tsukio, Y., Murakami, A., *et al.* (2001). Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. *Life Sciences*, 69(16), 1935-1945.
- Tedgui, A. and Mallat, Z. (2006). Cytokines in atherosclerosis: pathogenic and regulatory pathways. *Physiological Reviews*, 86(2), 515-581.
- Topper, J. N., Cai, J., Falb, D. and Gimbrone, M. A. (1996). Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proceedings of the National Academy of Sciences*, 93(19), 10417-10422.
- Toss, H., Lindahl, B., Siegbahn, A. and Wallentin, L. (1997). Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. *Circulation*, 96(12), 4204-4210.
- Toth, P. P. and Davidson, M. H. (2010). High-density lipoproteins: marker of cardiovascular risk and therapeutic target. *Journal of Clinical Lipidology*, 4(5), 359-364.

- Tsujimoto, A., Takemura, G., Mikami, A., Aoyama, T., Ohno, T., Maruyama, R., *et al.* (2006). A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. *Journal of Cardiovascular Pharmacology*, 48(4), 160-165.
- Tzeng, T.-F. and Liu, I.-M. (2013). 6-Gingerol prevents adipogenesis and the accumulation of cytoplasmic lipid droplets in 3T3-L1 cells. *Phytomedicine*, 20(6), 481-487.
- Tzeng, T.-F., Liou, S.-S., Chang, C. J. and Liu, I.-M. (2013). The Ethanol Extract of Zingiber zerumbet Attenuates Streptozotocin-Induced Diabetic Nephropathy in Rats. *Evidence-Based Complementary and Alternative Medicine*, 2013, 12.
- Tzeng, T.-F., Liou, S.-S., Chang, C. J. and Liu, I.-M. (2013). Zerumbone, a tropical ginger sesquiterpene, ameliorates streptozotocin-induced diabetic nephropathy in rats by reducing the hyperglycemia-induced inflammatory response. *Nutrition & Metabolism*, 10(1), 64.
- Tzeng, T.-F., Lu, H.-J., Liou, S.-S., Chang, C. J. and Liu, I.-M. (2014). Lipid-lowering effects of zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, in high-fat diet-induced hyperlipidemic hamsters. *Food and Chemical Toxicology*, 69, 132-139.
- Tzoulaki, I., Murray, G. D., Lee, A. J., Rumley, A., Lowe, G. D. and Fowkes, F. G. R. (2005). C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population Edinburgh artery study. *Circulation*, 112(7), 976-983.
- Unit, E. S. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*, 366, 1267-1278.
- Verma, S. and Singh, S. (2008). Current and future status of herbal medicines. *Veterinary World*, 1(11), 347-350.
- Verma, S., Singh, M., Jain, P. and Bordia, A. (2004). Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits. *Indian Journal of Experimental Biology*, 42(7), 736.
- Victor, V. M., Rocha, M., Sola, E., Banuls, C., Garcia-Malpartida, K. and Hernandez-Mijares, A. (2009). Oxidative stress, endothelial dysfunction and atherosclerosis. *Current Pharmaceutical Design*, 15(26), 2988-3002.
- Vimala, S., Norhanom, A. and Yadav, M. (1999). Anti-tumour promoter activity in Malaysian ginger rhizobia used in traditional medicine. *British Journal of Cancer*, 80(1/2), 110.
- Virchow, R. L. K. (1860). *Cellular Pathology: As Based Upon Physiological and Pathological Histology*. Philadelphia: J.B. Lippincott
- Von Rokitansky, C. and Swaine, W. E. (1855). *A Manual of Pathological Anatomy* (Vol. 3). Philadelphia: Blanchard & Lea.

- Wahab, A., Ibrahim, S., Abdul, A. B., Alzubairi, A. S., Mohamed Elhassan, M. and Mohan, S. (2009). In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa). *Journal of Biomedicine and Biotechnology*, 2009, 10.
- Weber, C. and Noels, H. (2011). Atherosclerosis: current pathogenesis and therapeutic options. *Nature Medicine*, 17(11), 1410-1422.
- Weerasinghe, P., Hallock, S. and Liepins, A. (2001). Bax, Bcl-2, and NF- κ B expression in sanguinarine induced bimodal cell death. *Experimental and Molecular Pathology*, 71(1), 89-98.
- Wenhong, D., Jia, Y., Weixing, W., Xiaoyan, C., Chen, C., Sheng, X., *et al.* (2012). Zerumbone attenuates the severity of acute necrotizing pancreatitis and pancreatitis-induced hepatic injury. *Mediators of Inflammation*, 2012, 156507-156507.
- Wilcox, J. N., Subramanian, R. R., Sundell, C. L., Tracey, W. R., Pollock, J. S., Harrison, D. G., *et al.* (1997). Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 17(11), 2479-2488.
- Williams, K. J. and Tabas, I. (1995). The response-to-retention hypothesis of early atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 15(5), 551-561.
- Williams, K. J. and Tabas, I. (1998). The response-to-retention hypothesis of atherogenesis reinforced. *Current Opinion in Lipidology*, 9(5), 471-474.
- Winther, M. P., van Dijk, K. W., Havekes, L. M. and Hofker, M. H. (2000). Macrophage scavenger receptor class AA multifunctional receptor in atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 20(2), 290-297.
- Woolf, N. (1990). Pathology of atherosclerosis. *British Medical Bulletin*, 46(4), 960-985.
- www.heart.org. (2013). CONDITIONS / Cholesterol / Why Cholesterol Matters / Atherosclerosis (Vol. 305564). Dallas: American Heart Association.
- www.members.iinet.net.au. (2009). Exotic Tropical Plants. *Wild Ginger Zingiber zerumbet*
- Xian, M., Ito, K., Nakazato, T., Shimizu, T., Chen, C. K., Yamato, K., *et al.* (2007). Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas and mitochondria mediated pathway. *Cancer Science*, 98(1), 118-126.
- Yamamoto, Y. and Gaynor, R. B. (2001). Role of the NF- κ B pathway in the pathogenesis of human disease states. *Current Molecular Medicine*, 1(3), 287-296.

- Yanni, A. E. (2004). The laboratory rabbit: an animal model of atherosclerosis research. *Laboratory Animals*, 38(3), 246-256.
- Yob, N., Jofrry, S. M., Affandi, M., Teh, L., Salleh, M. and Zakaria, Z. (2011). Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses. *Evidence-Based Complementary and Alternative Medicine*, 2011, 12.
- Yodkeeree, S., Sung, B., Limtrakul, P. and Aggarwal, B. B. (2009). Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. *Cancer Research*, 69(16), 6581-6589.
- Yuan, Y., Li, P. and Ye, J. (2012). Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. *Protein & Cell*, 3(3), 173-181.
- Zakaria, Z. A., Mohamad, A. S., Ahmad, M., Mokhtar, A., Israf, D. A., Lajis, N. H., *et al.* (2011). Preliminary analysis of the anti-inflammatory activity of essential oils of Zingiber zerumbet. *Biological Research for Nursing*, 13(4), 425-432.
- Zakaria, Z. A., Mohamad, A. S., Chear, C., Wong, Y., Israf, D. A. and Sulaiman, M. R. (2010). Antiinflammatory and antinociceptive activities of Zingiber zerumbet methanol extract in experimental model systems. *Medical Principles and Practice*, 19(4), 287-294.
- Zannis, V. I., Kypreos, K. E., Chroni, A., Kardassis, D. and Zanni, E. E. (2004). Lipoproteins and atherogenesis. *Molecular Mechanisms of Atherosclerosis*, 8, 111-174.
- Zeng, Y., Song, J. X. and Shen, X. C. (2012). Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. *Phytotherapy Research*, 26(2), 159-167.
- Zhang, S., Liu, Q., Liu, Y., Qiao, H. and Liu, Y. (2012). Zerumbone, a southeast Asian Ginger Sesquiterpene, induced apoptosis of pancreatic carcinoma cells through p53 signaling pathway. *Evidence-Based Complementary and Alternative Medicine*, 2012.
- Zheng, S., Qian, Z., Tang, F. and Sheng, L. (2005). Suppression of vascular cell adhesion molecule-1 expression by crocetin contributes to attenuation of atherosclerosis in hypercholesterolemic rabbits. *Biochemical Pharmacology*, 70(8), 1192-1199.
- Zulkhairi, A., Zaiton, Z., Jamaluddin, M., Sharida, F., Mohd, T., Hasnah, B., *et al.* (2008). Alpha lipoic acid posses dual antioxidant and lipid lowering properties in atherosclerotic-induced New Zealand White rabbit. *Biomedicine & Pharmacotherapy*, 62(10), 716-722.